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ABSTRACT 
Recent advances in transcriptome analysis have revealed that a large proportion of the 
mammalian genome is transcribed. Thousands of these transcripts are classified as long 
non-coding RNAs (lncRNAs), with size larger than 200 nucleotides, but very few have 
been functionally characterized. Here, I detail a journey of the discovery and analysis of 
lncRNAs in gene expression control and cell cycle progression, beginning from the 
characterization of a mutual regulation between lncRNA MALAT1 and its natural 
antisense transcript TALAM1, followed by the identification and functional 
characterization of lncRNAs involved in cell cycle progression. The mutual regulation 
between MALAT1 and TALAM1 presents a novel feed-forward positive regulatory loop 
at the MALAT1 locus where MALAT1 positively regulates the transcription and stability 
of TALAM1, and TALAM1 in turn promotes the processing and maturation events of 
MALAT1 which are essential to maintain the high cellular levels of MALAT1. In the 
characterization of functional lncRNAs in cell cycle progression, I focus on an S phase-
upregulated lncRNA, termed S7, and demonstrate that it plays crucial roles in cell cycle 
progression and tumorigenicity, through regulating the expression of genes in the cellular 
proliferation network including the Hippo signaling pathway. Altogether, these studies 
support a model whereby pervasive lncRNA transcripts, previously regarded as 
transcriptional byproducts, function through diverse mechanisms as critical regulators of 
gene expression and the vital cell cycle processes. 
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CHAPTER 1. INTRODUCTION 
1.1 Long noncoding RNA overview 
The genome transcriptome analyses have revealed that ~50-70% of the human genome is 
transcribed, out of which only 2% of the transcriptional output represent protein coding 
sequences (International Human Genome Sequencing Consortium 2004) (Birney et al, 
2007; Mattick, 2009). Thus, the large fraction of the genome transcribes RNA that do not 
code for proteins and such transcripts are classified as non-coding RNAs (ncRNAs) 
(Mattick, 2005; Mattick & Makunin, 2006; Prasanth & Spector, 2007). Although many 
housekeeping non-coding transcripts, like tRNAs, rRNAs, snRNAs, snoRNAs, RNaseP 
RNAs, are known to play crucial roles in key cellular processes, there’s still an ongoing 
debate on the biological relevance of the vast majority of the uncharacterized and several 
as yet unidentified ncRNAs (Ponjavic et al, 2007; Struhl, 2007). The evolutionary 
conservation (Guttman et al, 2009; Ponjavic et al, 2007; Ponting et al, 2009), specific 
subcellular localization (Chen & Carmichael, 2009; Chen & Carmichael, 2010; Clemson 
et al, 2009; Cohen & Panning, 2007; Hutchinson et al, 2007; Sasaki et al, 2009; Sone et 
al, 2007; Sunwoo et al, 2009; Tripathi et al, 2010), spatial and temporal expression 
pattern (Blackshaw et al, 2004; Cawley et al, 2004; Dinger et al, 2008; Dinger et al, 2009; 
Mercer et al, 2008; Ravasi et al, 2006; Rinn et al, 2007), and association with disease 
(Costa, 2005; Huarte & Rinn, 2010; Perez et al, 2008; Prasanth & Spector, 2007; Qureshi 
et al, 2010; Szymanski et al, 2005) of a significant number of these transcripts favor the 
argument that these ncRNAs are not merely by products of promiscuous transcription, 
rather they are an integral part of an extensive RNA control network that co-exist along 
with proteins (Mercer et al, 2009). Moreover, genomic analyses have shown that the 
protein-coding contribution of genome scales down with the increase in the 
developmental and physiological complexity of organisms (Mattick, 2003; Mattick, 2005; 
Mercer et al, 2009), suggesting the existence of a parallel regulatory network governed 
by the non-coding RNA counterparts.  
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Among these mysterious non-coding RNAs, transcripts larger than 200 nucleotides have 
been classified as long noncoding RNAs (lncRNAs) (Lipovich et al, 2010; Mercer et al, 
2009; Nagano & Fraser, 2011; Prasanth & Spector, 2007; Wilusz et al, 2009). Also, based 
on their genomic position with respect to protein-coding genes, lncRNAs are further 
classified as overlapping, cis-antisense, bidirectional, promoter- and 3’UTR-associated, 
enhancer-associated and intronic or intergenic lncRNAs (Lipovich et al, 2010; Orom & 
Shiekhattar, 2011).  This shifts our linear view of genome organization to a more 
complex one in which a series of sense and antisense, coding and non-coding transcripts 
can arise from the same genomic segment. The most recent estimation of the number of 
lncRNAs is human genome is ~59,000(Iyer et al, 2015). Only less than 1% of the 
lncRNA have been well characterized, suggesting that there is quite a long way to go 
before we unravel the functional relevance of all these RNAs.  
Most of the lncRNAs are transcribed by RNA polymerase II (RNA pol II), but several of 
them are also transcribed by RNA polymerase III (Dieci et al, 2007; Prasanth & Spector, 
2007). Although lncRNAs share the conventional chromatin signature of RNA Pol II 
transcription units, including histone 3 lysine 4 [H3K4] trimethylation mark at the 
promoter regions and H3K36 trimethylation mark within the transcription body (Guttman 
et al, 2009; Khalil et al, 2009; Wang et al, 2011b), recent studies have revealed unique 
features of lncRNAs in their biogenesis, processing and degradation processes, which 
distinguish them from mRNAs(Quinn & Chang, 2016). These unique regulatory 
mechanisms of lncRNAs’s metabolism may have contributed to the exceptional cell type 
and cell state specificity of lncRNAs’ expression pattern (Cabili et al, 2011; Derrien et al, 
2012).  
Not only the expression pattern, but also the specific sub-cellular localization of lncRNAs 
is highly regulated and context dependent. Specific lncRNAs are distributed either in the 
nucleus or in the cytoplasm and execute their functions within specific sub-cellular 
2 
 
compartments (Chen & Carmichael, 2010; Clark & Mattick, 2011). Several of the 
nuclear-retained ncRNAs (nrRNAs) localize to specific sub-nuclear compartments and 
are suggested to play structural roles or act as regulators of gene expression (Chen & 
Carmichael, 2010; Clark & Mattick, 2011). The RNA sequence and structure offer 
nrRNAs two inherent functional properties: 1) sequence-mediated interaction with 
genomic DNA or other RNA, and 2) secondary/tertiary structure-mediated interaction 
with RNA-binding proteins. NrRNAs can modulate gene expression by their potential 
capability to function as cofactors for their protein partners and even as scaffold 
molecules for combinatorial complex assembly at specific DNA/RNA locus. In support 
of this concept, increasing numbers of nuclear RNAs have been shown to participate in 
regulating gene expression at epigenetic, transcriptional and post-transcriptional level. 
With these versatile functions, lncRNAs play important roles in normal cell physiology 
and development. In addition, there is a growing cohort of lncRNAs whose abnormal 
expression has been found to be associated with various diseases, including cancer, 
neurological(Briggs et al, 2015) and immunological disorders(Esteller, 2011). These 
findings elicit questions regarding the basic mechanisms of lncRNAs’ functions and 
highlight the importance of understanding lncRNA mechanics in disease pathogenesis. 
1.2 Mechanisms of lncRNAs’ functions 
Chromatin modifications 
Recent genome-wide studies have suggested that a large proportion of nuclear lncRNAs 
are involved in regulating gene expression in an allele or cell-type specific manner 
through chromatin modification by targeting chromatin modifying complexes in cis or 
trans to specific genomic loci(Engreitz et al, 2016; Rinn & Chang, 2012). Examples of 
nuclear RNAs involved in dosage compensation include Xist, Tsix, RepA, Jpx and roXs. 
Similarly, nuclear RNAs implicated in genome imprinting are Air and Kcnq1ot1.  
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Dosage compensation is one of the earliest examples where lncRNAs have been 
identified to play crucial roles in the chromatin modification events. Multiple lncRNAs 
participate in the inactivation of one of the two X-chromosomes in female mammals (Lee, 
2009; Lee, 2010; Masui & Heard, 2006; van Bemmel et al, 2016). LncRNA XIST/Xist 
(X-inactive specific transcript) (~16 kb) is the major player in the X-chromosome 
inactivation (XCI). LncRNA Xist is transcribed from and coats the future inacivative X 
chromosome (Xi) in cis. The Xist gene lies within the X-inactivation center (Xic), a 
region on the X that is required for XCI. The Xist RNA has been functionally dissected 
into three regions: the most conserved A-repeat region at the 5’ end which are crucial in 
X-linked gene silencing, followed by a middle region for polycomb repressive complex 2 
(PRC2) recruitment to chromatin, and the long 3’ end region for Xist RNA coating of the 
Xi(van Bemmel et al, 2016). Xist triggers a cascade of events that lead to transcriptional 
silencing, conformational reorganization and heterochromatinization of Xi. At the onset 
of XCI, Xist RNA promotes the transcriptional silencing through interacting with 
multiple protein partners. SHARP/SPEN, an RNA binding protein involved in 
transriptional repression, binds directly to the 5’ end Xist A-repeat region, and interacts 
with the SMRT deacetylase complex responsible for the deacetylation of histones via 
HDAC3. This silencing complex was found to be essential for subsequent PRC2 
recruitment on the Xi (McHugh et al, 2015). Moveover, RNA binding proteins RBM15 
and RBM15B interact with Xist and recruit the m6A RNA methylation machinery WTAP 
and MTTL3 which methylates the adenosine residues of Xist. Then the YTHDC1 reader 
binds m6A residues and promotes the Xist-mediated transcriptional silencing. Xist RNA 
also functions through interacting with the nuclear scaffold/matrix protein HNRNPU 
which is involved in tethering of Xist to the Xi, as well as Lamin B receptor which 
recruits Xi to the nuclar lamina, changing the 3D structure of DNA, enabling Xist and its 
interacting silencing proteins to spread across the Xi to silence transcription (da Rocha & 
Heard, 2017). Moreover, it was proposed that the three-dimentional genome architecture 
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also plays a role in guiding Xist to spread across the X chromosome (Engreitz et al, 
2013).  
In addition to Xist, multiple lncRNAs are transcribed from the Xic and contributes to 
XCI by regulating the expression of Xist. These lncRNAs include RepA, Jpx and Ftx as 
positive regulators of Xist, as well as Tsix, the antisense and negative regulator of Xist, 
together with Linx, Xite and Tsx which are activators of Tsix (van Bemmel et al, 2016). 
Interestingly, the chromosome interaction map from 5C studies revealed that the Xic 
actually displays a structural organization in two topologically associating domains 
(TADs), segregating the Xist promoter and its cis activator segments from the Tsix 
promoter and its respecitve regulators (Nora et al, 2012; van Bemmel et al, 2016).  
In Drosophila, the dosage compensation of X-chromosome is achieved by the 
hyperactivation of the single X-chromosome in male flies. Nuclear-retained, roX 
lncRNAs (roX-1 and 2) are specifically transcribed from the male X-chromosome and are 
part of the chromatin remodeling complex that facilitates the hyperactivation of genes 
encoded on the male X-chromosome (Ilik & Akhtar, 2009). Similarly, allele specific gene 
silencing is also brought about by the imprinted nuclear lncRNAs like Air and Kcnq1ot1 
that function by recruiting polycomb proteins and histone methyltransferases to specific 
gene loci (Nagano & Fraser, 2011).  
Besides dosage compensation, another source of excitement of lncRNAs in epigenic gene 
regulation came from the studies of lncRNA HOTAIR and its trans regulation. HOTAIR 
lncRNA (~2.2kb) is transcribed from the boundary of the two diametric chromatin 
domains in the HOX C locus, which is one of the four HOX genes clusters located on 
different human chromosomes (Hung & Chang, 2010; Rinn et al, 2007; Tsai et al, 2010). 
The noncoding regions in HOX clusters are ultraconserved among mammalian genome 
and give rise to ~230 novel ncRNAs. HOTAIR silences the transcription of HOX D locus, 
physically interact with the PRC2 complex, and depletion of HOTAIR impacts PRC2 
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localization at its target sites (Rinn et al, 2007). With regard to its importance in 
development, controversial phenotypes recently rose from studies on HOTAIR knockout 
mouse, which may be at least partially due to the differences in the genetic background of 
mouse as well as sample dissection (Amandio et al, 2016; Li et al, 2013; Selleri et al, 
2016). Interestingly, HOTAIR is highly upregulated in primary and metastatic breast 
tumors, and its overexpression is correlated with both metastasis and poor survival rate 
(Gupta et al, 2010). Overexpression of HOTAIR results in genome-wide retargeting of 
PRC2, altered pattern of H3K27 methylation and increases invasiveness, whereas 
depletion of HOTAIR impedes metastasis of PRC2-overactive cells (Gupta et al, 2010). 
Furthermore, HOTAIR was found to bridge PRC2 and LSD1/COREST/REST complexes 
together via its 5’ and 3’ domains, respectively (Tsai et al, 2010).  It was therefore 
proposed that lncRNAs like HOTAIR coordinate coupling of H3K27 methylation and 
H3K4 demethylation.  
PRC2 is a critical chromatin regulatory complex that catalyses the methylation of histone 
H3 at lysine 27 and compacts chromatin. PRC2 has important roels in maintaining cell 
identity, stem-cell plasticity, differentiation and proliferation. Although polycomb 
proteins are critical in transcriptionally silencing the chromatin, they have very limited 
DNA binding specificity. Therefore, their specific recognition of target chromatin regions 
requires the assistance of other cofactors(Margueron & Reinberg, 2011). In mammals, 
how PRC2 is recruited to chromatin is not yet clear. The discovery that the Xist and 
HOTAIR lncRNAs silence transcription, physically interact with the PRC2 complex and 
that perturbation of these RNAs impacts PRC2 localization at their target sites(Rinn et al, 
2007; Zhao et al, 2008b) raised great interest in the interactions of lncRNAs with PRC2 
and the functional roles of these interactions. Numerous studies then uncovered hundreds 
of lncRNAs that interact with PRC2 (Khalil et al, 2009; Zhao et al, 2010b). Since in 
mammals PRC2 lacks clear DNA sequence specificity, these results led to a model  
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whereby lncRNAs guide PRC2 to specific targets on DNA to control chromatin 
modification and gene expression.  
However, there are several emerging challenges to this “lncRNA guide PRC2” model. 
First, PRC2 components were found to interact promiscuously with virtually all RNAs 
(Davidovich et al, 2015; Davidovich et al, 2013; Kaneko et al, 2013). Secondly, a recent 
study, which tethered HOTAIR to a reporter gene locus with or without depleting the 
cellular PRC2 components, revealed that the transcriptional silencing is dependent on the 
presence of HOTAIR lncRNA at the promoter region, but does not depend on its 
interaction with PRC2 (Portoso et al, 2017). Taken together, it appears that PRC2 binds to 
lncRNAs promiscuously and these interactions are not required for regulation of gene 
expression. Furthermore, these results argue that HOTAIR recruitment of PRC2 to 
genomic DNA is not dependent on the RNA interaction with PRC2. Instead, PRC2 
recruitment and H3K27me3 deposition likely occur as a consequence of 
HOTAIR-dependent gene silencing, rather than through a direct RNA-mediated 
recruitment mechanism (Blanco & Guttman, 2017). Consistent with this indirect 
recruitment model, it is now clear that gene silencing can lead to the recruitment of PRC2 
to genomic DNA (Riising et al, 2014). With this notion in mind that PRC2 recruitment 
maybe a consequence of HOTAIR-mediated gene silencing, then defining the upstream 
mechanism of how HOTAIR actually silences transcription will require unbiased in vivo 
characterization of its binding proteins using stringent denaturing purification methods, 
examplified by the discovery of SHARP/SPEN in mediating Xist’s function in XCI 
(McHugh et al, 2015).  
Antisense transcript-mediated silencing is also emerging as a widely applied strategy in 
epigenetic gene silencing. Examples include ANRIL lncRNA, which recruits PRC1 and 2 
complexes to INK4A/ARF/INK4b gene cluster and influences the silencing of the genes 
within this locus (Kotake et al, 2011; Yap et al, 2010). Similarly, P15AS, Khps1 and 
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rDNA-promoter antisense ncRNAs modulate region-specific DNA methylation by 
recruiting different combinations of DNA methylases and demethylases (Imamura et al, 
2004; Schmitz et al, 2010; Yu et al, 2008).  
Besides lncRNAs like HOTAIR and ANRIL that act as negative regulators of gene 
expression, there are several examples of lncRNAs that maintain active chromatin status, 
indicating the existence of potential RNA network that controls transcription by 
influencing chromatin structure. Examples include the recently identified HOTTIP RNA, 
which targets WDR5/MLL complexes across HOXA cluster via chromosome looping 
(Wang et al, 2011a) and Jpx RNA that acts as an activator of Xist expression by 
extricating CTCF from the Xist allele on Xi (Sun et al, 2013).  
Transcriptional Regulation 
LncRNAs have been known to regulate transcription through diverse mechanisms (Clark 
& Mattick, 2011; Lipovich et al, 2010; Nagano & Fraser, 2011; Wang et al, 2011b). 
LncRNAs can directly influence general transcription factor loading at specific chromatin 
sites. For example, lncRNA transcribed from the upstream region of the DHFR gene 
locus impedes transcription from the DHFR major promoter region by forming a triplex 
structure with the DHFR promoter DNA (Martianov et al, 2007). This lncRNA also 
interacts with TFIIB general transcription factor and facilitates the disassociation of 
preinitiation complex from the DHFR major promoter. Similarly, human Alu RNA and 
mouse SINE B2 RNA are suggested to bind and block the DNA-binding channel of RNA 
pol II during heat shock and thus repress global RNA pol II-mediated transcription (Allen 
et al, 2004; Espinoza et al, 2004; Mariner et al, 2008; Yakovchuk et al, 2009). Some 
lncRNAs can also serve as cofactors to recruit and modulate the activity of transcription 
factors. For example, the steroid receptor RNA activator (SRA) is a 700bp lncRNA, 
operating as part of a ribonucleoprotein complex, which coactivates several 
steroid-hormone receptors (Hatchell et al, 2006; Lanz et al, 1999; Zhao et al, 2004). 
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Recently a lincRNA, lincRNA-p21, transcribed from the intergenic region upstream of 
p21/cdkn1a locus has been found to be induced by p53.  LincRNA-p21 is required for 
p53-mediated repression of genes involved in apoptosis, partially via orienting hnRNP-K 
to the promoters of specific genes that need to be repressed. In this scenario, hnRNP-K is 
proposed to exert its transcriptional repressive functions through interacting with other 
repressive complexes such as histone H1.2 or members of the polycomb proteins (Huarte 
et al, 2010). Another example includes, Evf2, a mouse brain specific lncRNA transcribed 
from the intergenic enhancer region of Dlx-5/6 loci. EvF2 recruits the homeodomain 
transcription factor Dlx-2 in cis and induces the Dlx-5/6 enhancer activity resulting in the 
elevated expression of Dlx-5 and -6 (Feng et al, 2006). LncRNAs transcribed from the 
5’regulatory regions of Cyclin D1 (CCND1) gene negatively regulate CCND1 
transcription during genotoxic stress, by recruiting factors and chromatin modifying 
enzymes at CCND1 gene locus (Wang et al, 2008; Wang et al, 2011b).    
The role of lncRNAs in enhancer activity in human cells was promoted by the 
identification of a set of lincRNAs with enhancer-like function (Orom et al, 2010; Orom 
& Shiekhattar, 2011). Earlier studies have reported that many of the well-known enhancer 
elements are actively transcribed, including those in the iconic globin locus control 
region (Ashe et al, 1997), HS2 enhancer (Kong et al, 1997)  and neuronal 
activity-regulated enhancers (Kim et al, 2010). Later some of these enhancer-associated 
lncRNAs were found to be integral to the functions of the enhancers which they are 
transcribed from, by regulating their target genes through a variety of mechanisms, from 
controlling promoter chromatin accessibility, RNAPII loading, chromatin loop formation 
and pause release to modulating TF-DNA binding (Li et al, 2016).   
Besides the above examples in which the lncRNA molecules have a gene regulatory 
mode of action, there are also examples where the transcription process of lncRNAs itself, 
is enough to promote or repress the transcription of adjacent genes. This is achieved 
either via progressive opening of chromatin structure to increase the accessibility of 
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transcription factors, or conversely via transcription interference where the ongoing 
lncRNA transcription impedes the initiation and/or progression of another transcription 
from the overlapping region. A subset of enhancers transcibe enhancer RNAs, and the 
enhancers’ function does not depend on the enhancer RNAs per se, but rather requires the 
transcription process which remodels the chromatin (Li et al, 2016). Theorectically, the 
transcribing RNAPII is a DNA motor that has dramatic architectural effects on local 
chromatin(Herbert et al, 2008), and its CTD serves as a ‘landing pad’ that can bind more 
than 100 proteins with various functions tro ‘travel together’(Bentley, 2014; Li et al, 
2016). Experimentally, the function of the enhancer RNA transcription process is 
supported by a study on a specific cohort of de novo enhancers where inhibition of 
enhancer transcriptional elongation reduced the deposition of H3K4me1 and H3K4me2 
owing to compromised ‘travelling’ of the responsible histone methyltransferase 
associated with RNAPII (Kaikkonen et al, 2013). While for transcriptional interference, it 
was observed in case of Fbp1+ and SRG1 lncRNA transcribing units in S. pombe (Hirota 
et al, 2008), and S.cerevisae respectively (Martens et al, 2004; Martens et al, 2005). It 
was also reported that two intronic transcribing enhancers modulate the isoform decision 
of the overlapping sense coding genes by ‘transcriptional interference’ (Onodera et al, 
2012).  
Post-transcriptional Regulation 
At post-transcriptional level, lncRNAs can function as regulators of pre-mRNA splicing 
(Luco & Misteli, 2011). Natural antisense transcripts (NATs) regulate splicing of the 
overlapping sense transcripts (Hastings et al, 2000; Krystal et al, 1990; Munroe & Lazar, 
1991), as has been observed in the case of Zeb2/Sip1 mRNA splicing. Zeb2/Sip1 is a 
transcriptional repressor of E-cadherin and is upregulated during epithelial-mesenchymal 
transition (EMT) (Beltran et al, 2008). The Zeb2/Sip1 intron contains an internal 
ribosomal entry site (IRES), which is necessary for the translation of Zeb2/Sip1. In 
normal epithelial cells, the Zeb2 is not expressed due to the removal of the intron 
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containing the IRES. Upon EMT, a NAT is transcribed from a region that is 
complementary to the intron containing the IRES. This NAT prevents the splicing of the 
IRES containing intron from the mRNA, resulting in the efficient translation of Zeb2 
mRNA (Beltran et al, 2008).  
Stress-induced repeat containing lncRNAs have also been speculated to regulate 
pre-mRNA splicing by sequestering pre-mRNA splicing factors (Biamonti & Caceres, 
2009; Biamonti & Vourc'h, 2010; Jolly & Lakhotia, 2006a). Examples include the hsrω-n 
RNA in fruit flies and the Sat III transcripts in mammalian cells (Biamonti & Caceres, 
2009; Biamonti & Vourc'h, 2010; Jolly & Lakhotia, 2006a). Others and we have recently 
demonstrated that Metastasis associated lung adenocarcinoma transcript 1 (MALAT1) 
lncRNA also play a pivotal role in alternative splicing regulation (Bernard et al, 2010; 
Lin et al, 2011; Tano et al, 2010; Tripathi et al, 2010). 
LncRNAs can also recognize mature mRNAs in the cytoplasm and regulate their half-life 
and translation. Staufen1 (STAU1)-mediated mRNA decay (SMD) promotes the 
degradation of a large population of translationally active mRNAs which binds to STAU1 
at their 3’UTRs. Many of its target mRNAs do not harbor the complete double-stranded 
RNA stem region for the binding of STAU1, and their efficient degradation requires a 
group of lncRNAs named as half-STAU1-binding site RNAs (1/2-sbsRNAs). 
1/2-sbsRNAs contain Alu elements which can bind to the Alu elements in the 3’UTR of 
target mRNAs and transactivate the STAU1-mediated mRNA decay towards these target 
mRNAs(Gong & Maquat, 2011). Another example is lncRNA TINCR which programs 
STAU1 to promote mRNA stability. TINCR is induced during epidermal differentiation, 
localizes to the cytoplasm, where it identifies mRNAs with the TINCR box motif, 
recruits STAU1 to these mRNAs and mediate their stabilization. This process ensures the 
expression of these differentiation mRNAs and is critical for the induction of key 
mediators during epidermal differentiation (Kretz et al, 2013). In addition, lncRNAs can 
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also positively and negatively impacts the translation of target mRNAs, examples include 
antisense Uchl1 lncRNA and lincRNA-p21 respectively. Upon stresses which inhibit 
cap-dependent translation, antisense Uchl1 lncRNA translocates from nucleus to 
cytoplasm and hybridizes with Uchl1 mRNA to enable cap-independent translation of 
Uchl1, via acting like a mobile internal ribosomal entry element to promote selective 
translation(Carrieri et al, 2012). lincRNA-p21, whose stability is negatively regulated by 
HuR, on the opposite, hybridizes to target mRNAs and represses their translation, thereby 
acting as a mediator for HuR’s regulation of translation efficiency(Yoon et al, 2012).  
There are also lncRNAs exerting their post-transcriptional regulatory roles by 
sequestrating proteins away from their normal sites of action. For example, the large 
intergenic spacer (IGS) of the rDNA repeats expresses a specific group of ncRNAs. 
Different IGS ncRNAs are expressed upon specific environmental stress conditions, 
functions as baits for proteins with specific signal peptide, and immobilize them at the 
nucleolus detention centers under stress conditions (Audas et al, 2012).  
Structural Organization of Nuclear Bodies 
Besides the above roles of lncRNAs in chromatin modifications, transcriptional and 
post-transcriptional gene regulation, they also actively participate in the establishment, of 
specific subnuclear structures or domains (Chen & Carmichael, 2010; Shevtsov & Dundr, 
2011). For example, the MEN ε /β locus in mouse (Neat1 in human) codes for two 
nuclear lncRNAs (>3 and 17 kb) that localize to paraspeckle subnuclear domain, and is 
the main structural RNA component of paraspeckles (Chen & Carmichael, 2009; 
Clemson et al, 2009; Sasaki et al, 2009; Sunwoo et al, 2009). Paraspeckles form in close 
proximity to the site of MEN ε /β transcription, and the MEN β lncRNA serves as the 
platform to recruit proteins for paraspeckle assembly. Both the MEN β RNA itself and 
the transcription of MEN ε /β gene are essential for paraspeckle formation and 
maintenance (Mao et al, 2011; Naganuma et al, 2012). Though the exact role of 
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paraspeckle remains to be elucidated, several studies have indicated that paraspeckles 
regulate gene expression by sequestrating proteins, such as SFPQ, or mRNAs with 
inverted repeats in their 3’UTRs (Bond & Fox, 2009; Chen & Carmichael, 2010; Chen et 
al, 2008; Fox & Lamond, 2010; Hu et al, 2016; Prasanth et al, 2005). Recently, via 
super-resolution structured illumination microscopy, it was found paraspeckles are 
organized in a core-shell spheroidal structure composed of MEN β RNA and seven 
paraspeckle proteins: SFPQ, NONO, PSPC1and FUS are the core components of 
paraspeckles, which exclusively colocalized with the middle region of MEN β RNA in 
the center of paraspeckles; the patch proteins RBM14 and BRG1 were mainly found in 
the core and shell parts of paraspeckles; and the shell protein TDP43 was predominantly 
enriched in the periphery of paraspeckles (West et al, 2016). 
In Drosophila melanogaster, the developmentally regulated and stress inducible 93D 
locus encodes hsrω (heat shock RNA omega) ncRNA gene that transcribes multiple 
lncRNAs through alternative polyadenylation and splicing (Jolly & Lakhotia, 2006a; 
Lakhotia, 2003; Mutsuddi & Lakhotia, 1995). The nuclear-retained long (~15 kb) hsrω-n 
ncRNA, transcribed from the hsrω locus localizes to nuclear omega speckles along with 
several other pre-mRNA processing factors (Prasanth et al, 2000). Further, hsrω-n 
transcript is essential for the omega speckle integrity, as cells devoid of hsrω-n fail to 
form omega speckles (Prasanth et al, 2000). Similar to omega speckles, a specific 
sub-nuclear domain called nuclear stress bodies (nSBs) in mammalian cells also contain 
several pre-mRNA processing factors including SR family of splicing factors and an 
lncRNA transcribed from the Sat III repeats from chromosome 9q12 region (Biamonti & 
Vourc'h, 2010; Chiodi et al, 2000; Denegri et al, 2001; Denegri et al, 2002; Jolly et al, 
2004). The stress-induced nSBs are formed at the Sat III lncRNA transcription sites and 
the accumulation and relocalization of nuclear proteins to nSBs is strictly dependent on 
the presence of sat III transcripts, indicating the crucial role played by sat III transcripts 
in the formation of nSBs (Biamonti & Vourc'h, 2010). It is speculated that both omega 
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speckles and nSBs are dynamic sites where several of the pre-mRNA processing factors 
are sequestered during cellular stress and the ncRNAs within them play vital roles in the 
formation and/or maintenance of these domains and are also involved in modulating 
pre-mRNA processing (Biamonti & Caceres, 2009; Jolly & Lakhotia, 2006b).  
Recent studies have demonstrated that nuclear RNAs can initiate the assembly of the 
nuclear bodies preferentially by acting as nucleation sites for the recruitment and 
accumulation of specific nuclear proteins (Mao et al, 2011; Shevtsov & Dundr, 2011). 
Together, these observations reveal a crucial role for RNA in the dynamic assembly, 
organization and maintenance of nuclear bodies. 
1.3 LncRNAs in disease 
With the acknowledgement of the diverse functions of lncRNAs in cellular networks, 
increasing lncRNAs contributing to diseases are being identified(Esteller, 2011). For 
example, Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal-dominant 
disease associated with reduction in the copy number of the D4Z4 repeat mapping to 
4q35. In normal subjects, the high number of D4Z4 repeats allows the attachment of 
PRC2 to the DNA, promoting the maintenance of repressed chromatin through histone 3 
lysine 27 trimethylation, DNA methylation, and histone deacetylation marks. Conversely, 
in FSHD patients, reduction in D4Z4 repeats diminishes the presence of PRC2, causing 
the chromatin to open, and resulting in the transcription of a chromatin-associated 
lncRNA, named as DBE-T. DBE-T then contributes to the pathology of FSHD by 
recruiting the Trithorax group protein Ash1L to the FSHD locus, which drives histone H3 
lysine 36 dimethylation, chromatin remodeling, and the de-repression of 4q35 gene 
(Cabianca et al, 2012). Other examples of lncRNAs involved in disease progression 
includes HELLP lncRNA in HELLP (hemolysis, elevated liver enzymes, low platelets) 
syndrome (van Dijk et al, 2012), and BACE1-AS lncRNA in Alzheimer’s disease 
(Faghihi et al, 2008). 
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With regard to cancer, recent genome-wide association studies have revealed that most of 
the cancer-associated haplotypes identified in genome wide association studies reside in 
the noncoding regions of the genome, a large number of which produce long noncoding 
RNAs(Edwards et al, 2013). HOTAIR lncRNA is one the first lncRNAs whose roles in 
human cancers have been well-studied. In epithelial cancer cells, HOTAIR 
overexpression induces genome-wide re-targeting of Polycomb repressive complex 2 to 
an occupancy pattern more resembling embryonic fibroblasts, and increases cancer 
invasiveness and metastasis(Gupta et al, 2010). p15AS lncRNA, which is the antisense 
lncRNA for p15 is another example of oncogenic lncRNA. It was first identified in 
human leukaemia and shown to induce the silencing of the p15 tumor suppressor gene 
locus through inducing the formation of heterochromatin (Yu et al, 2008).  
Later more lncRNAs have been found to drive cancer phenotypes through modulating 
various aspects of cancer progression, from proliferation (eg. MALAT1, CTBP1-AS, 
PCGEM1, PRNCR1, HOTAIR, PVT1, CCAT1-L, CARLo-5, PCAT-1), growth 
suppression (eg. TARID, MEG3, MIR31HG, lincRNA-p21, LED, FAL1, LINC-PINT, 
TUG1, NBAT1, PR-lncRNA-1, PR-lncRNA-10, PTENP1), viability (eg. GAS5, PANDA, 
NORAD), immortality (eg. NBAT-1, TINCR, TERRA, TERC), motility (eg. MALAT1, 
lncRNA-ATB, BCAR4, HOTAIR, SChLAP1, NKILA, PTENP1, SCHLAP1), to 
angiogenesis (eg. HULC, MVIH) (Huarte, 2015; Schmitt & Chang, 2016).   
These examples motivated me to study this group of novel molecules with diverse 
functions but yet limited prior knowledge of their functions, in the context of normal cell 
physiology and cancer development. In Chapter 3, I studied novel lncRNAs that are 
involved in cell cycle regulation and tumorigenesis. 
1.4 LncRNA MALAT1 and its 3’ end processing 
MALAT1 is a highly abundant linear lncRNA which localizes to nuclear speckles and is 
implicated in pre-mRNA splicing and transcriptional activation of genes involved in 
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cell-growth and proliferation (Li et al, 2009; Tripathi et al, 2010; Tripathi et al, 2013; 
Yang et al, 2011b; Zong et al, 2011). The strikingly high cellular accumulation of 
MALAT1 [MALAT1 exists in ~2500-3000 copies per cell (Tripathi et al, 2010), with a 
half-life up to 16.5 hours (Gutschner et al, 2013)] has been attributed to an unusual 
processing and maturation event at its ultra-conserved 3’ end: The primary transcripts of 
MALAT1 harbors a tRNA-like structure at its 3’ end, which is recognized and cleaved by 
tRNA processing enzymes RNase P and RNase Z. This process generates a cytoplasmic 
tRNA-like small RNA, known as mascRNA, and mature nuclear retained MALAT1 
lncRNA. The mature MALAT1 lncRNA lacks canonical poly(A) tail, but forms bipartite 
triple helical structures at its 3’ ends which confer resistance against 
exonucleases-mediated RNA degradation (Brown et al, 2014; Brown et al, 2012). This 
triple helix is formed through engaging two upstream U-rich motifs and a 3’ terminal 
genome-encoded A-rich tract (Brown et al, 2014). Based on the sequence, structure and 
function, the two highly conserved U-rich motifs are proposed to be the cellular homolog 
of the Expression and Nuclear retention Element (ENE) discovered in viral lncRNAs, 
which is known to protect viral lncRNAs from rapid nuclear deadenylation-dependent 
decay pathway, through clamping the poly(A) tail of viral lncRNA into a similar triple 
helical structure (Brown et al, 2014; Brown et al, 2012; Mitton-Fry et al, 2010; Wilusz et 
al, 2008; Wilusz et al, 2012). Slightly different from the ENE-containing viral lncRNAs, 
the stable formation of the triple helix in MALAT1 requires the mascRNA cleavage 
reaction to generate a blunt end in the triple helix (Brown et al, 2014; Brown et al, 2012; 
Conrad, 2014). The fully processed mature MALAT1 is localized in nuclear speckles, 
where it plays crucial roles in regulating the organization and activities of several 
pre-mRNA splicing factors and transcription factors (Li et al, 2009; Tripathi et al, 2010; 
Tripathi et al, 2013; Yang et al, 2011b; Zong et al, 2011). In accordance with its 
pro-proliferative molecular functions, upregulation of MALAT1 has been identified as a 
hallmark of tumor progression and metastasis in multiple cancers (Gutschner et al, 2013).  
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Despite the above-described characterization of the unusual 3’ end processing of 
MALAT1 and the identification of the genome-encoded sequence motifs mediating this 
processing event, how this post-transcriptional processing event is regulated, the event 
that is crucial for the enhanced stability of MALAT1, remains to be understood. In the 
following Chapter 2, I investigated the role of natural antisense transcript in modulating 
MALAT1’s 3’ end processing event and identified a novel feed-forward positive 
regulatory loop at the MALAT1 locus established to maintain the high cellular levels of 
MALAT1.  
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CHAPTER 2. NATURAL ANTISENSE RNA PROMOTES 3’ END PROCESSING 
AND MATURATION OF MALAT1 LNCRNA 
2.1 Introduction 
Long noncoding RNAs (lncRNAs) function in every step of gene regulation by 
modulating the activity of several protein-coding genes (Rinn & Chang, 2012; Wang & 
Chang, 2011). Most lncRNAs are transcribed by RNA polymerase II (RNA Pol II), and 
they share similar features with mRNAs, including having a 5’ cap structure and 3’ 
poly(A) tails (Wang & Chang, 2011). The 3’ end processing of RNA is critical for the 
termination of RNA Pol II and also determines the stability, subcellular localization and 
eventually the functionality of the mature RNA (Lutz & Moreira, 2011; Tian & Manley, 
2013). Recent studies have reported the existence of non-canonical 3’ end processing 
mechanisms at several lncRNA loci that generate non-polyadenylated RNAs (Wilusz & 
Spector, 2010; Yang et al, 2011a; Zhang et al, 2014). Among them, metastasis-associated 
lung adenocarcinoma transcript 1 (MALAT1) (also known as NEAT2) and multiple 
endocrine neoplasia-β (MENβ) (also known as NEAT1) RNAs are unique as they are 
highly abundant linear transcripts. For example, MALAT1 exists in ~2500-3000 
copies/cell (Tripathi et al, 2010), with a half-life up to 16.5 hours (Gutschner et al, 2013). 
In contrast, other non-polyadenylated lncRNAs like enhancer RNAs and circular RNAs 
are present in low abundance and exhibit less stability (Zhang et al, 2014). 
The strikingly high cellular accumulation of MALAT1 and MENβ has been attributed to 
an unusual processing and maturation event at their ultra-conserved 3’ ends (Brown et al, 
2014; Brown et al, 2012; Wilusz et al, 2008; Wilusz et al, 2012): The primary transcripts 
of both MALAT1 and MENβ harbor a tRNA-like structure at their 3’ end, which are 
recognized and cleaved by tRNA processing enzymes RNase P and RNase Z. This  
 
 
 
Chapter 2 has been published with few modifications as:  
Zong X, Nakagawa S, Freier SM, Fei J, Ha T, Prasanth SG, Prasanth KV (2016) Natural 
antisense RNA promotes 3' end processing and maturation of MALAT1 lncRNA. Nucleic 
Acids Res., 44(6):2898-908. 
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process generates a cytoplasmic tRNA-like small RNA, known as mascRNA for 
MALAT1 and menRNA for MENβ, along with mature nuclear retained MALAT1 and 
MENβ lncRNAs. The mature MALAT1 and MENβ lncRNAs lack canonical poly(A) tail, 
but form bipartite triple helical structures at their 3’ ends, which confer resistance against 
exonuclease-mediated RNA degradation (Brown et al, 2014; Brown et al, 2012). This 
triple helix is formed through engaging two upstream U-rich motifs and a 3’ terminal 
genome-encoded A-rich tract (Brown et al, 2014). Based on the sequence, structure and 
function, the two highly conserved U-rich motifs are proposed to be the cellular homolog 
of the Expression and Nuclear retention Element (ENE) discovered in viral lncRNAs. 
The viral ENE is known to protect viral lncRNAs from rapid nuclear 
deadenylation-dependent decay pathway, through clamping the poly(A) tail of viral 
lncRNA into a triple helical structure similar to that of MALAT1 and MENβ (Brown et al, 
2014; Brown et al, 2012; Mitton-Fry et al, 2010; Wilusz et al, 2008; Wilusz et al, 2012). 
Slightly different from the ENE-containing viral lncRNAs, the stable formation of the 
triple helix in MALAT1 and MENβ requires the mascRNA/menRNA cleavage reaction to 
generate a blunt end in the triple helix (Brown et al, 2014; Brown et al, 2012; Conrad, 
2014). The fully processed mature MALAT1 is localized in nuclear speckles, where it 
plays crucial roles in regulating the organization and activities of several pre-mRNA 
splicing factors and transcription factors (Li et al, 2009; Tripathi et al, 2010; Tripathi et al, 
2013; Yang et al, 2011b; Zong et al, 2011). In accordance with its pro-proliferative 
molecular functions, upregulation of MALAT1 has been identified as a hallmark of tumor 
progression and metastasis in multiple cancers (Gutschner et al, 2013).   
Although the post-transcriptional processing of MALAT1 3’ end has been recognized to 
be crucial for the enhanced stability of MALAT1, how this processing event is regulated 
is not well understood. In the present study, we identified a natural antisense transcript 
(NAT) at the MALAT1 locus, which we named as TALAM1. TALAM1 contributes to the 
stability of MALAT1 by promoting the 3’ end cleavage and maturation of MALAT1. 
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Meanwhile, MALAT1 RNA positively regulates the transcription and stability of 
TALAM1, and thereby establishes a feed-forward positive regulatory loop at the 
MALAT1 locus to achieve high cellular levels of MALAT1. 
2.2 Results 
2.2.1 Identification of TALAM1, a natural antisense transcript at the MALAT1 locus 
A natural antisense transcript (NAT) of ~6kb long at the mouse Malat1 locus was initially 
reported in mouse embryonic stem cells (Zhao et al, 2010b). To verify the existence of 
this NAT in other species and cell types, we examined the presence and relative 
abundance of this NAT in various human cell types, including human diploid fibroblasts 
(WI-38) and multiple cancer cell lines. The conventional RT-qPCR strategy, utilizing 
gene specific RT primer and PCR primer pairs (without linkers) (Figure 2.1Aa), does not 
always provide strand specificity, and detects both sense and antisense transcripts (Figure 
2.1Ab and see legends for details) (Tuiskunen et al, 2010; Vashist et al, 2012). To 
specifically detect and quantify the NAT and MALAT1 sense transcript, we applied a 
strand-specific reverse transcription and real time PCR strategy (ssRT-qPCR) that was 
previously used to strand-specifically detect viral transcripts(Figure 2.1B and see also 
Materials and Methods) (Vashist et al, 2012). Specific detection of NAT using 
ssRT-qPCR in various cell types indicated that NAT from MALAT1 locus is widely 
expressed in several human cell lines (Figure 2.2A). We named this NAT as TALAM1, 
since it is transcribed from the complementary strand of MALAT1 gene. RNA expression 
analyses in different cell types revealed a positive correlation in the levels of TALAM1 
and MALAT1, indicating potential co-regulation of these transcripts (Figure 2.2A). 
Further, copy number analysis in HeLa cells revealed TALAM1 is ~290-fold less 
abundant than the highly abundant MALAT1 RNA (Figure 2.3). 
We next performed rapid amplification of cDNA ends (RACE) and directional 
sequencing to determine the 5’ and 3’ ends of TALAM1.  RACE analyses identified 
human TALAM1 as a ~8.1kb long transcript (Figure 2.2B, Figure 2.4). This includes a 
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7.1kb region that completely overlaps with MALAT1 sense transcript, and a 5’ end ~1kb 
unique region that extends beyond the 3’ end of MALAT1 gene (Figure 2.2B). Northern 
blot analysis using a probe that mostly spans the unique 5’ end of TALAM1 detected 
specific TALAM1 signal at the expected 8kb position (Figure 2.5). Analysis of the 5’ end 
sequence of TALAM1 in UCSC (University of Santa-Cruz) genome browser revealed 
signatures of an active promoter, including chromatin immunoprecipitation (ChIP) 
signals of RNA Pol II, numerous transcription factors, as well as histone modifications 
associated with active transcription (H3K4me3, H3K4me1, H3K27Ac) (Figure 2.6A). 
RNA fractionation using Oligo-dT columns, together with the 3’ RACE and Northern blot 
data, confirmed TALAM1 as a polyadenylated transcript (Figure 2.6B). These results 
together indicate TALAM1 as a novel NAT from the MALAT1 locus, which is subject to 
active RNA Pol II transcriptional regulation.  
To determine the cellular localization of TALAM1, RNA-fluorescent in situ hybridization 
(RNA-FISH) was performed in HeLa cells (Figure 2.2C, upper panel). In contrast to 
MALAT1, which is primarily enriched in nuclear speckles, TALAM1 displayed weak 
homogenous nuclear distribution, with preferential enrichment at 2 to 4 nuclear foci 
where it co-localizes with MALAT1 RNA (see arrows in Figure 2.2C, upper panel). 
These foci were further demonstrated to be the transcription sites of the MALAT1 gene 
loci, as they completely co-localized with the DNA FISH signals targeting the MALAT1 
genomic DNA loci (see arrows in Figure 2.2C, bottom panel).  
To address the potential co-regulation between MALAT1 and TALAM1, we first 
examined the level of TALAM1 in wild type (WT) and Malat1 knockout (KO) mouse 
embryonic fibroblast (MEF) cells. This Malat1 KO mouse was generated by inserting a 
LacZ-polyadenylation signal cassette at 69bp downstream of the Malat1 promoter, 
thereby disrupting the transcription from the Malat1 promoter, without changing any 
sequences of the Malat1 gene locus, including the region corresponding to Talam1 gene 
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(Nakagawa et al, 2012). TALAM1 levels were consistently low in both heterozygous and 
homozygous Malat1 null MEFs (Figure 2.2D), suggesting that the TALAM1 levels are 
dependent on either the transcription of MALAT1 or the presence of MALAT1 transcripts. 
To distinguish between these two scenarios, we utilized MALAT1-specific antisense 
oligos (ASO) to deplete MALAT1 transcripts, without affecting the transcription of 
MALAT1 (Tripathi et al, 2010; Zong et al, 2015). In MALAT1-depleted human cells, 
TALAM1 level was found to decrease dramatically (Figure 2.2E), indicating that the 
maintenance of TALAM1 levels in cells requires the presence of MALAT1 transcripts. 
2.2.2 MALAT1 RNA positively regulates the transcription and stability of TALAM1 
RNA 
The cellular pool of RNAs could be regulated at the level of both transcription as well as 
post-transcriptional processing and stability. We first examined whether MALAT1 
positively regulates TALAM1 through promoting its transcription. RNA Pol II occupancy 
at the TALAM1 promoter showed ~50% reduction upon MALAT1 depletion, indicating 
that active transcription of TALAM1 requires the presence of MALAT1 RNA (Figure 
2.7A and B). To assess whether the stability of TALAM1 RNA is also dependent on 
MALAT1, we determined TALAM1 RNA stability in control versus MALAT1-depleted 
cells, via Actinomycin D chase experiment. Actinomycin D is an RNA Pol II inhibitor 
that blocks nascent RNA synthesis. In control cells, TALAM1 was a relatively stable 
RNA, with a half-life of ~8 hours. However, in cells depleted of MALAT1, the half-life 
of TALAM1 reduced dramatically to ~2-3 hours (Figure 2.7C and Figure 2.8). To identify 
whether this regulation of TALAM1 by MALAT1 acts in cis or in trans, we utilized a 
MALAT1 construct with point mutations conferring resistance to ASO knockdown, and 
observed that the exogenously expressed, ASO-resistant MALAT1 transcripts could 
rescue in trans the levels of endogenous TALAM1 in cells that were depleted of 
endogenous MALAT1 (Figure 2.9A). To further analyze the requirement of sequence 
complementarity between MALAT1 and TALAM1 in conferring the stability, we 
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overexpressed human MALAT1 in Malat1 KO transformed MEFs and assessed whether 
exogenously expressed human MALAT1 could rescue the levels of endogenous mouse 
Talam1.  Our results revealed that the exogenously expressed human MALAT1 
transcripts could not rescue the endogenous mouse Talam1 (Figure 2.9B), suggesting that 
the rescue may require higher level of sequence complementarity between these two 
transcripts at certain crucial sequence motifs. Collectively, our data demonstrate that 
MALAT1 RNA positively regulates the transcription as well as the stability of TALAM1 
RNA.  
The positive regulation of NATs by their sense transcripts could be achieved via the 
formation of RNA duplex, which alters the secondary or tertiary structure of RNA, 
thereby influencing RNA stability (Faghihi et al, 2008; Johnsson et al, 2013; Mahmoudi 
et al, 2009; Yuan et al, 2014). To test the existence of RNA duplex formed between 
MALAT1 and TALAM1, an in vivo RNase protection assay was performed (Ogawa et al, 
2008). While non-overlapping regions of MALAT1 and TALAM1 were almost 
completely degraded by RNase A (Figure 2.7A, 7Da & Db, primer sets 1 and 4), multiple 
sites in the overlapping regions were protected from degradation (Figure 2.7A, 7Da & Db, 
primer sets 2 and 3). The protection ratio 0.1%~0.5% is in consistency with the previous 
copy number data that TALAM1 is ~290-fold less abundant than MALAT1 (Figure 2.3), 
which means for every 1 molecule of TALAM1, there will be 290 molecules of MALAT1, 
and therefore, 1 RNA duplex can be formed between TALAM1 and MALAT1, which can 
protect the RNA from RNaseA-mediated degradation. Thus, the protection ratio will be 
1/(290+1)≈0.34%. As a positive control, a similar protection was observed in case of 
BACE1 transcript, which is known to form RNA duplexes with its NAT in vivo (Faghihi 
et al, 2008) (Figure 2.7D). Our results indicate that significant proportions of TALAM1 
and MALAT1 indeed form RNA duplex in vivo, possibly occurring at the sites of their 
transcription, which in turn could positively influence the stability of both the transcripts.   
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2.2.3 TALAM1 is required for the efficient 3’ end processing and cellular 
accumulation of MALAT1 lncRNA 
Next, to determine the cellular function of TALAM1, we assessed whether TALAM1 
could also regulate MALAT1. First, to deplete TALAM1, we screened a set of 
strand-specific ASOs targeting the 5’ unique region of TALAM1. We consistently 
achieved ~50% of TALAM1 depletion using two independent ASOs (Figure 2.10A). 
Remarkably, TALAM1-depleted cells showed a concomitant reduction in MALAT1 
levels (Figure 2.10A) as determined by ssRT-PCR, suggesting TALAM1 RNA also 
positively influences the cellular levels of MALAT1.  
Based on recent studies, the cellular accumulation of MALAT1 depends on its efficient 3’ 
end cleavage and the formation of the 3’ end triple helix structure (Brown et al, 2014; 
Brown et al, 2012). Our observation that TALAM1 depletion results in a decrease in the 
total cellular pools of MALAT1, prompted us to explore whether TALAM1, with its 
ability to form duplex with MALAT1, could regulate the 3’ end processing of MALAT1. 
The cleaved mature form of MALAT1 was reported to be the dominant form, while the 
uncleaved precursor exists at a very low level (Wilusz et al, 2008). To distinguish these 
two forms of MALAT1 RNA, and to quantitatively detect the potential changes in their 
levels, we modified a RNA cutoff assay, a technique that was previously used to 
determine pre-microRNA processing in cells (Legnini et al, 2014; Martin & Keller, 1998) 
(Figure 2.10B and see also Materials and Methods). In cells where TALAM1 has been 
reduced to ~50% (Figure 2.10A, TALAM1-ASO-treated sample), we observed an 
increase in the level of uncleaved MALAT1 (Figure 2.10C), together with a concomitant 
decrease in the level of mascRNA (Figure 2.10D), suggesting a compromised efficiency 
of MALAT1 3’ end processing event (see also Figure 2.11).  2’MOE-modified DNA 
ASOs with sequence complementary to mascRNA site and 2’-O-methoxy-ethyl ribose 
phosphorothioate backbone, which imparts high affinity for targeted RNA but does not 
activate RNase H-mediated target RNA cleavage, has been previously applied to inhibit 
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MALAT1 3’ end cleavage in mouse cells (Wilusz et al, 2008). We utilized a similar 
approach, and treated human cells with 2’MOE ASO complementary to the human 
mascRNA cleavage site. The human 2’MOE ASO successfully inhibited MALAT1 
cleavage, as reflected by the decrease in mascRNA level, and a concomitant increase in 
the level of uncleaved precursor MALAT1 (Figure 2.10E), confirming the specificity of 
our RNA cutoff assay. In addition, similar to TALAM1-ASO-treated samples (Figure 
2.10A), the total cellular level of MALAT1 also showed a reduction in the 
2’MOE-treated sample (Figure 2.10E).  This data supports the current model that 
efficient MALAT1 3’ end processing is required for the high cellular accumulation of 
MALAT1 (Brown et al, 2014; Brown et al, 2012). And our results showing similar effects 
exerted by TALAM1-ASO and MALAT1-2’MOE in altering the ratio of uncleaved to 
cleaved MALAT1 RNA as well as total MALAT1 levels strongly indicate that TALAM1 
promotes the cellular accumulation of MALAT1 through facilitating its 3’ end processing 
and maturation event.  
2.2.4 TALAM1 promotes the 3’ end processing of MALAT1 
In order to gain insights into the involvement of TALAM1 in the 3’ end processing of 
MALAT1, we determined the effect of TALAM1 overexpression on endogenous 
MALAT1. Upon TALAM1 overexpression, even though the total cellular level of 
MALAT1 remained unaffected (Figure 2.12), there was a small but consistent increase in 
the level of cleaved mature MALAT1, with a concomitant reduction in the level of 
uncleaved precursor MALAT1 (Figure 2.13A). In addition to assessing the levels of 
cleaved versus uncleaved MALAT1, mascRNA level could serve as another indicator of 
the efficiency of the cleavage reaction. Since TALAM1 does not influence the total level 
of MALAT1 (Figure 2.12), we could exclude the possibility that TALAM1 enhances the 
expression of MALAT1, thus producing more mascRNA. In cells that overexpress 
TALAM1, a significant increase in mascRNA level was revealed by Northern blot 
analyses (Figure 2.13Ba). MascRNA-specific Taqman small RNA RT-qPCR assay also 
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showed consistent increase in the level of mascRNA in TALAM1 overexpressed cells 
(Figure 2.13Bb). The relative increase in the levels of mascRNA and cleaved MALAT1, 
together with the decrease in uncleaved MALAT1 upon TALAM1 overexpression, 
suggest that transiently overexpressed TALAM1 could facilitate in trans the 3’ end 
processing of MALAT1. It is important to note that we observed the effects on the 
cleavage of endogenous MALAT1 only when we overexpressed TALAM1 to ~300 fold. 
However, under physiological conditions, TALAM1 is a low copy transcript, and 
primarily enriched at the site of transcription. Based on our results, TALAM1 may 
primarily function in cis, and the trans effect that we observed requires large amount of 
TALAM1 RNA. 
The stabilization effect of the MALAT1 3’ end sequence has been recently characterized 
using an in vivo reporter decay system, where the MALAT1 3’ end ENE+A+mascRNA 
sequence cassette stabilizes an intronless β-globin transcript (βΔ1,2) against the rapid 
RNA decay in vivo (Brown et al, 2014; Brown et al, 2012). We therefore exploited this 
reporter system to evaluate the physiological significance of TALAM1 in modulating the 
stabilization activity of the MALAT1 ENE+A+mascRNA cassette. The βΔ1,2 gene 
containing the MALAT1 ENE+A+mascRNA in its 3’ untranslated region was placed 
under the control of doxycycline responsive promoter (Figure 2.13Ca).  This reporter 
construct was transfected along with empty vector or TALAM1 overexpression construct 
into a U2OS Tet-off cell line. Cells that overexpressed TALAM1 consistently showed 
increased stability of the βΔ1,2 transcript  (Figure 2.13Cb). This result indicates that 
TALAM1 could facilitate the stability of even a reporter RNA containing the MALAT1 
ENE+A+mascRNA cassette. 
To address if TALAM1 directly promotes the 3’ end processing event, we set up an in 
vitro processing assay, using in vitro transcribed 32P-labeled MALAT1 3’ end fragment, 
containing the MALAT1 ENE+A+mascRNA sequence, as substrate. This substrate was 
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incubated with HeLa cell extract, with or without the addition of in vitro transcribed 
TALAM1 RNA. Since it is technically challenging to in vitro transcribe ~8000nt long 
TALAM1 RNA, we generated fragments of TALAM1 to cover the 5’ half of TALAM1 
full length RNA, including TALAM1-F1R1, a 2600nt fragment from the 5’ end region of 
TALAM1 that harbors the complementary sequence to the 3’ end of MALAT1, and 
TALAM1-F2R2, a successive 3000nt fragment from the middle region of TALAM1 
overlapping with MALAT1 (Figure 2.13Da). When incubated with HeLa cell extract, the 
MALAT1 ENE+A+mascRNA fragment was processed to produce the 61nt mascRNA 
(Figure 2.13Db, lanes 3, 8). MascRNA production was efficiently blocked by 
MALAT1-2’MOE ASO, confirming the specificity of this reaction (Figure 2.13Db, lane 
2). With the addition of in vitro transcribed TALAM1-F1R1 and F2R2 together, a 
moderate and consistent increase in mascRNA level was observed (Figure 2.13Db, lane 5, 
10), indicating that TALAM1 could directly promote the 3’ end processing of MALAT1 
in vitro. To further map the TALAM1 sequence element, TALAM1-F1R1 or 
TALAM1-F2R2 was added individually to the cell extract. In comparison to F1R1 or 
F2R2 individually incubated extracts, TALAM1 F1R1+F2R2-incubated extract displayed 
highest mascRNA cleavage activity (Figure 2.13Db, compare lanes 5 or 10 with 6-7 or 
11-12, respectively). Unexpectedly, more activity was found to reside within 
TALAM1-F2R2 than TALAM1-F1R1 (Figure 2.13Db, compare lanes 6 with 7, and 11 
with 12). These modest effects were confirmed by multiple independent experiments 
(Figure 2.14), and the changes in mascRNA levels were summarized and quantified by 
Image J (Figure 2.13Dc).  The result that TALAM1-F2R2 is more potent than 
TALAM1-F1R1 in promoting the mascRNA cleavage in vitro, implies TALAM1 may not 
be functioning in a linear base-to-base manner, but instead, more complex secondary or 
tertiary structures may be formed between TALAM1-F2R2 and MALAT1 3’ end 
sequence. These interactions between TALAM1 and MALAT1 may facilitate the folding, 
and/or stabilize the tRNA structure to be efficiently recognized and cleaved by RNase P. 
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It is also possible that other factors may be recruited to MALAT1 by TALAM1-F2R2 to 
facilitate MALAT1 cleavage reaction.   
LncRNA MENβ is the other example of cellular RNAs that have been so far identified to 
undergo similar 3’ end processing event. Strand-specific RT-PCR analyses revealed the 
presence of NAT at the MENβ locus close to the menRNA site (Figure 2.15), suggesting 
NAT could be a general feature that is required for efficient 3’ end cleavage of cellular 
RNAs containing ENE and tRNA-like structures at their 3’ end. 
2.3 Discussion 
MALAT1 localizes to nuclear speckles and has been implicated in pre-mRNA splicing 
and transcriptional activation of genes involved in cell-growth and proliferation (Li et al, 
2009; Tripathi et al, 2010; Tripathi et al, 2013; Yang et al, 2011b; Zong et al, 2011). 
Upregulation of MALAT1 is observed to be widely associated with hyper-proliferation 
and metastasis in cancer, and the oncogenic activity of MALAT1 has been documented in 
several types of cancers (Gutschner et al, 2013).  In the present study, we have identified 
TALAM1, a NAT from the MALAT1 locus, as an important positive regulator of 
MALAT1 through promoting its 3’ end processing event, a step that is crucial for 
stabilizing MALAT1 RNA. TALAM1 was found to positively influence the cellular 
accumulation of MALAT1 and could promote the stabilization effect of MALAT1 3’ end 
sequence towards labile RNA. Further, TALAM1 itself is positively regulated by 
MALAT1, thereby forming a feed-forward regulatory loop to maintain the high cellular 
levels of MALAT1 (Figure 2.16). 
The cellular accumulation of MALAT1 RNA has been found to rely on the presence of 
the ENE+A sequence, which forms a triple helix after the 3’ end processing events 
(Brown et al, 2014; Brown et al, 2012; Wilusz et al, 2008; Wilusz et al, 2012). MALAT1 
constructs lacking the ENE sequence, when transiently expressed in cells, showed 
reduced stability, indicating the requirement of ENE in stabilizing MALAT1 RNA 
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(Brown et al, 2014). Further, crystallography studies confirmed the formation of a 
bipartite triple helical structure within the ENE elements and the A-rich tract. Such a 
structure is demonstrated to confer resistance to exonucleases (Brown et al, 2014; Conrad, 
2014). The cleavage of mascRNA from the primary MALAT1 transcript generates a blunt 
end in the triple helix, removing the steric hindrance, and is required for the stable 
formation of the triple helix. This was demonstrated by crystallography analyses as well 
as by mutational studies, where removal of mascRNA as the cleavage signal or creation 
of terminal nucleotides overhangs greatly diminished the stability of reporter constructs 
containing MALAT1 3’ end sequence (Brown et al, 2014; Brown et al, 2012; Conrad, 
2014). Therefore, in addition to the triple helical structure, which is encoded in the 
MALAT1 sequence, the stability of MALAT1 transcript is also controlled by the efficient 
3’ end post-transcriptional cleavage.  Our loss- and gain-of-function analyses revealed 
that TALAM1 positively regulates the 3’ end cleavage of MALAT1. Importantly, 
TALAM1 depletion phenocopies the MALAT1-2’MOE ASO treatment. Both of these 
treatments impair MALAT1 3’ end cleavage, thereby dramatically reducing MALAT1 
cellular levels. Our data altogether support TALAM1 as an important positive regulator 
of MALAT1 3’ end processing, a step that is required for the stabilization of MALAT1 
transcripts.  
At present it is not clear how TALAM1 modulates the 3’ end cleavage of MALAT1. 
TALAM1 RNA concentrates predominantly at the MALAT1 gene locus and could form 
RNA duplex structures with MALAT1 RNA. At the same time, exogenous expression 
studies indicate that upon overexpression, TALAM1 could also exert its function in trans. 
It is possible that TALAM1, by interacting with MALAT1, modulates the secondary and 
tertiary structure of MALAT1 RNA, and this could influence the recognition of 
tRNA-structure in uncleaved MALAT1 by RNase P.  Eukaryotic RNase P is a 
ribonucleoprotein complex, consisting of catalytic H1 RNA and multiple protein subunits. 
The protein subunits within the RNase P complex are involved in substrate recognition 
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and binding, regulation of enzymatic activity as well as structural organization of the 
RNP complex. The differential distribution of H1 RNA and the protein subunits in 
distinct sub-nuclear compartments as well as the rapid mobility of some subunits within 
the nucleus, suggest that the assembly of the RNase P could be dynamic and subject to 
regulation (Jarrous, 2002; Jarrous & Gopalan, 2010; Jarrous & Reiner, 2007). Earlier 
studies have also documented the roles of specific co-factors in regulating RNase P 
activity. For example, the human La antigen directly interacts with precursor tRNAs and 
blocks the site of cleavage, thereby preventing precursor tRNA from being processed by 
RNase P (Jarrous, 2002). Thus, it is also possible that TALAM1 may facilitate the 
recruitment of specific components of the RNase P complex or its cofactors to MALAT1 
RNA, or act as a decoy to sponge inhibitory protein factors away from MALAT1 RNA 
(Figure 2.16). Future studies will probe into the mechanistic insights of TALAM1, and 
potentially other NATs, in RNase P-mediated cleavage of non-canonical substrates, 
including MALAT1 and additional cellular RNAs with ENE-like structures.  
MALAT1’s important role in normal cell physiology and its pathophysiological 
dysregulation in cancer highlight the importance of maintaining a tight and robust 
regulatory control of MALAT1 expression (Gutschner et al, 2013). A few earlier studies 
have described the involvement of transcriptional and post-transcriptional processes that 
regulate MALAT1 expression (Gutschner et al, 2013). Based on our results, we speculate 
that the levels of TALAM1 could contribute to differential stability of MALAT1. In 
support of this, we found TALAM1 and MALAT1 are co-expressed with a positive 
correlation in multiple human and mouse cell lines. However, although we have 
demonstrated TALAM1 as a regulator of MALAT1 3’ end processing as well as cellular 
accumulation, how much is this TALAM1-mediated post-transcriptional regulation 
contributing to the dysregulation of MALAT1 during tumorigenesis, remains to be 
explored. In addition, even though we find a feedback loop through which MALAT1 
positively regulates TALAM1 levels, the regulation of TALAM1 expression by other 
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cellular factors and pathways, for example, by the transcription factors, which interact 
with TALAM1 promoter (Figure 2.6A), awaits further investigation. It would be 
interesting to determine whether specific oncogenic pathways regulate TALAM1 levels 
in order to increase MALAT1 levels. In this context, it would be fruitful to profile human 
cancers with upregulated MALAT1 levels, and determine whether the elevated MALAT1 
levels are attributed to its enhanced stability, altered efficiency in 3’ end processing and 
dysregulated expression of TALAM1.  
Antisense transcription has been recently recognized as a widespread feature of 
mammalian genome (Katayama et al, 2005). Arguing against the simplistic assumption of 
a negative regulatory role of antisense transcription through transcriptional collision, 
RNA-dependent heterochromatinization or formation of sense/antisense (S/AS) hybrids, 
which then are processed by RNAi machinery, a growing number of recent studies 
describe concordant regulation by S/AS pairs (Katayama et al, 2005; Villegas & 
Zaphiropoulos, 2015).  Multiple NATs have been found to be actively involved in 
promoting the expression of their sense transcripts, via various mechanisms, including 
DNA demethylation, chromatin remodeling, as well as post-transcriptional regulation of 
RNA stability, splicing and RNA editing (Faghihi & Wahlestedt, 2009). More specifically, 
stabilization of the sense RNA by NAT has been reported where the formation of RNA 
duplex is proposed to be responsible for stabilizing the sense RNA (Faghihi et al, 2008; 
Johnsson et al, 2013; Yuan et al, 2014). Importantly, some of these NATs are exploited by 
pathophysiological pathways to control the levels of their sense transcripts, as observed 
in the case of PTENpg1 asRNA in cancer (Johnsson et al, 2013), as well as BACE1-AS 
RNA in Alzheimer’s disease (Faghihi et al, 2008). Our study on TALAM1 provides 
unique insights into the utilization of NATs to modulate post-transcriptional 3’ end 
processing and stability of sense lncRNAs, especially for those regulatory RNAs whose 
vital cellular functions demand stringent expression control.  
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2.4 Materials and methods 
2.4.1 Strand-specific RT-qPCR and Taqman small RNA assay 
For strand-specific RT-qPCR, reverse transcription was performed using gene specific 
reverse transcription primers with a linker sequence at 5’ end, and then qPCR was 
performed using gene specific forward primer and the linker as reverse primer. Sequences 
of primers are listed in supplementary methods. qPCR analysis of human mascRNA was 
performed using Taqman small RNA assay (Life technologies, Assay ID: CSCSU4N), 
with U6 snRNA as internal loading control (Assay ID: 001973). 
2.4.2 RNA/DNA FISH 
A set of custom Stellaris® FISH probes comprising 17 single-labeled oligonucleotides 
designed for MALAT1 were purchased from Biosearch Technologies. TALAM1 probe 
was generated via nick-translation cDNA kit (Abbott Molecular, USA), using a 
pGEM-Teasy construct containing the 5’ 1kb unique region of TALAM1 as template. For 
RNA/DNA FISH, DNA FISH probe was generated via nick translation from BAC clone 
RP11-1104L6. For dual RNA FISH, the fixation and hybridization of HeLa cells were 
performed as described previously(Tripathi et al, 2015). For RNA/DNA FISH, the RNA 
FISH probe against TALAM1 was labeled with digoxigenin-11-dUTP using DIG nick 
translation mix (Roche), and fixation and hybridization of HeLa cells were performed as 
described previously(Rose Tam, 2002).  
2.4.3 Antisense oligonucleotide, 2’MOE 
Phosphorothioate internucleosidic linkage-modified DNA antisense oligonucleotides 
were used to deplete human MALAT1 and TALAM1. Uniform 2’-O-methoxy ethyl 
substituted oligonucleotides with a full phosphorothioate backbone and AGTmC were  
used to inhibit the mascRNA cleavage. These reagents were designed and synthesized by 
ISIS Pharmaceuticals, and their sequences are listed in supplementary methods.  
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2.4.4 RNA cutoff assay 
To specifically detect the levels of uncleaved and cleaved MALAT1, RNA samples were 
subject to PolyG tailing, before being reverse transcribed with Oligo dC primers tagged 
with an adaptor sequence. Poly G tailing was performed using yeast poly(A) polymerase 
(Affymetrix) and rGTP. After reverse transcription, qPCR was performed using the 
adaptor as common reverse primer, and gene-specific forward primers located upstream 
and downstream of mascRNA site to detect cleaved and uncleaved MALAT1, 
respectively. For internal control of RNA loading and reaction efficiency, a forward 
primer located at the 3’ end of GAPDH mRNA was used. Sequences of primers are listed 
in supplementary methods. 
2.4.5 Cell Culture 
HeLa, U2OS, MEFs were grown in DMEM containing high glucose, supplemented with 
10% fetal bovine serum (FBS) (Hyclone, Logan, UT) and penicillin-streptomycin (PS). 
WI-38 cells were grown in DMEM containing high glucose+10% FBS +1% non-essential 
amino acid+PS. HCT116 cells were grown in McCoy’s 5A medium+10%FBS+PS.  
2.4.6 Antisense oligonucleotide, 2’MOE, and DNA Transfection  
The ASOs were transfected to cells, at a final concentration of 100 nM for 
MALAT1-ASO for one time, and 200nM for TALAM1-ASO for twice (48hr) with a gap 
of 24 hr, using Lipofectamine RNAimax reagent (Invitrogen)(Zong et al, 2015). Lower 
concentration of TALAM1-ASOs at 50nM was used in Supplementary Figure S8 to 
minimize potential off-target effects. 2’ MOE ASOs were administered at a final 
concentration of 100nM to cells with Lipofectamine 2000 (Invitrogen), and the cells were 
collected after 24hrs. Plasmid DNAs were transfected into cells using Lipofectamine 
2000, and the cells were collected after 24hrs. The sequence of 2’MOE ASO to block 
human mascRNA cleavage is GTAGTCAAAGCAAAGACGCCGC. 
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2.4.7 Rapid Amplification of cDNA Ends (RACE) 
5’ and 3’ RACE were performed using the GeneRacer Kit (Invitrogen), according to the 
manufacturer recommendations. The primers for both 5’ and 3’ RACE are listed below. 
5-hTALAM1-R: TCCCTGCGGCGTCTTTGCTTTGA, 5-hTALAM1-Nest-R: 
CCTGCAG CTGGTGTTTTGAGAAGCCCTA, 3-hTALAM1-F: 
CGCAATTCTCCCTGCGTCATGGATTTCA. 
2.4.8 RT-qPCR and RT-PCR 
Total cellular RNA was extracted from the cells using Trizol (Invitrogen) as per 
manufacturer’s instructions and reverse transcribed into cDNA using Multiscribe Reverse 
transcriptase and either Random hexamers (Applied Biosystems) or gene specific primers. 
qPCRs were performed using StepOne Plus system (Applied Biosystems). Transcript 
levels were quantitated against a standard curve by Real-time RT-PCR using the SYBR 
Green I fluorogenic dye and data analyzed using the StepOne plus system software. 
Primer sets showing comparable high efficiencies were used for the analyses. The 
primers to detect human and mouse MALAT1 and TALAM1 were listed below: linker-R: 
CGACTGGAGCACGAGGACACTGA, 
hMALAT1-RT:CGACTGGAGCACGAGGACACTGATTATTTTAATCACCTACAAC, 
hMALAT1-F:ATACCAATAGAAGGGCAATG, 
hTALAM1-RT:CGACTGGAGCACGAGGACACTGAGGAGTTCTTAAATATCAACC
A, hTALAM1-F: GCCCACAGGAACAAGTCCTA, mMALAT1-RT: 
CGACTGGAGCACGAGGACACTGATTGTGGTAGGTCATCTGTTC, mMALAT1-F: 
AGCTTTTGAGGGCTGACTGC, mTALAM1-RT: 
CGACTGGAGCACGAGGACACTGAGCCTTTAGTCTCTTCCAGATT, mTALAM1-F: 
GCACTAAAGACCACGGAACT. The primers to detect NAT from human MENβ are: 
hMENβ-RT:CGACTGGAGCACGAGGACACTGAGGGATATCTTGTCTCCTAGAG, 
hMENβ-R: TCCTGGGAAGAAGAGGGCAGTGG, hMENβ-nest-R: 
GGATAGCAGGGCAGGAGGGCTTC. 
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2.4.9 RNA Cutoff Aassay Primer Sequences 
Adaptor sequence: GCTACGTAACGGCATGACA. For uncleaved MALAT1, the 
forward qPCR primer is: GAGAAGCCCTACTGCTGAAA; For cleaved MALAT1, the 
forward qPCR primer is: GGAAGCTGATCTCCAATGCT; For internal control GAPDH, 
the forward qPCR primer is: CTCCTCACAGTTGCCATGTA. 
2.4.10 Poly(A) RNA Purification 
The fractionation of poly(A) plus versus minus RNAs were performed using NucleoTrap 
mRNA kit (Clontech). After the purification, the yield of both fractions were quantified, 
and equal amount of RNA were taken for RT and qPCR analysis, and the fold of 
enrichment in either poly(A) plus or minus fractions were calculated by normalization the 
qPCR values of each fractions to the yield of the corresponding fraction.   
2.4.11 Chromatin Immunoprecipitation (ChIP) 
1×107 control and MALAT1-KD HeLa cells were fixed using 1% formaldehyde at room 
temperature for 10mins, then quenched with 125mM Glycine for 5 mins, and rinsed twice 
with ice cold PBS. Cells were then harvested and lysed in buffer containing 1% SDS, 
10mM EDTA, 50mM Tris, pH8.0. Chromatin was sonicated using Bioruptor Power-up 
(Diagenode) for 40~45 cycles of 30” on +30” off at high level, to obtain genomic DNA 
fragments tightly within 150-300 bp size range. Debris was pelleted by centrifuge at 
10000g at 4°C for 10 mins. Sheared chromatin was precleared using protein G Dynabeads 
(Life Technologies) for 2 h before incubation with Anti-RNA polymerase II antibody 
(Millipore, Cat# 05-623) or IgG overnight at 4 °C. Antibody-bound chromatin was pulled 
down using preblocked Dynabeads for 1.5 h. Beads were washed once each with low salt 
buffer (0.1% SDS; 1% Triton; 2 mM EDTA; 20 mM Tris, pH 8.0, 150 mM NaCl), once 
with high salt buffer (0.1% SDS; 1% Triton; 2 mM EDTA; 20 mM Tris, pH 8.0, 500 mM 
NaCl), once with LiCl wash buffer (10 mM Tris, pH 8.0; 1% Na-deoxycholate; 1% 
NP-40, 250 mM LiCl; 1 mM EDTA), and twice with TE (10 mM Tris, pH 8.0, 1 mM 
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EDTA). Chromatin was eluted in elution buffer (1% SDS, 0.1 M sodium bicarbonate) at 
65 °C twice, 10 min each. Cross-link was reversed with 0.2 M NaCl overnight at 65 °C. 
The eluted material was RNase A-treated followed by Proteinase K treatment at 42 °C for 
2 h. DNA was purified using QIAquick PCR purification kit (Qiagen). ChIP-qPCR results 
were represented as percentage of IP/input signal (% input). qPCR primers used for 
ChIP-qPCR as depicted in Figure 2A are: TALAM1 promoter region aF: 
TGTTTTTCCAAAGCAGAAGGTTCT, aR: GCCCCCAATTCCTACTCGTACT, 
upstream 4kb of TALAM1 TSS bF: CTCACGCCGGTAATCCAAGT, bR: 
GGCCATGTTGGTCTCAAACTC, GAPDH-F: TAGAGCGGCCGCCATGT, GAPDH-R: 
GCAGGAGCGCAGGGTTAGT, ACTB-F: CAGGGCTTCTTGTCCTTTC, ACTB-R: 
GGTACTTCAGGGTGAGGAT. 
2.4.12 RNA Stability Analysis 
RNA stability analysis was carried out by incubating 5μg/ml of Actinomycin D with 
control and MALAT1 knockdown cells. Samples were then collected at indicated time 
points, and the RNA levels at specific time points were normalized to 0h time point, that 
is, before the addition of Actinomycin D.   
2.4.13 In vivo RNAse Protection Assay 
4x106 HeLa cells were washed in PBS, pelleted, and resuspended in 1.5 ml of lysis buffer 
containing 10 mM Tris pH 7.4, 3 mM CaCl2, 2 mM MgCl2, and 0.7% NP-40. Lysates 
were passed through a 27.5 gauge needle five times, then placed on ice for 10 minutes. 
The solution was adjusted to 125 mM NaCl, and 12.5 units/ml of DNAse I(Sigma) was 
added. The 1.5ml lysate was then split into two equal aliquots. RNase A (Qiagen) to a 
final concentration of 200 ng/ml, was added to one aliquot; the other aliquot with 250 
units/ml of SUPERRnaseIn (Ambion) served as an RNAse-negative control. Samples 
were incubated at 37oC for 40 minutes. TrizolLS (Invitrogen) was added to stop the 
reaction and extract RNA; residual DNA was removed with the DNAse I(Sigma). The 
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protected RNAs were then subjected to Random hexamers-mediated RT-qPCR and 
RT-PCR. The primers to detect the overlapping region between BACE1 and BACE1-AS 
are BACE1-S-AS-F:  TGATGGATTTGACTACAGCTTCAA, and BACE1-S-AS-R: 
ATGACAAGAGCATTGTGGACAGT. Primers for MALAT1 and TALAM1 as depicted 
in Figure 2A are: 1F: GCTTGAGGAAACCGCAGATA, 1R: 
CGTTAAAAACTTAACGCTAAGCAA, 2F: CTTCCCTAGGGGATTTCAGG, 2R: 
GCCCACAGGAACAAGTCCTA, 3F: AACTGGCAAGTGGAAATGTTT, 3R: 
AAGACCAAGGGAGGGGAGA, 4F: CCTGGGTCACTCAGGATCACA, 4R: 
CACGTTCAAAGGGACAAAAGG. 
2.4.14 Northern Blots 
For mascRNA Northern, 2μg small RNAs were separated by 12% polyacrylamide/8M 
urea denaturing gel electrophoresis and electroblotted to Hybond N+ membrane (GE 
Healthcare). For TALAM1 Northern, 2~10μg poly(A) plus RNAs were separated by 1% 
agarose/formaldehyde gel prepared using NorthernMax denaturing gel buffer (Ambion), 
and transferred to Hybond N+ membrane via upward capillary transfer with 10×SSC. For 
northern blots using oligonucleotide probes, ULTRAhyb-Oligo Hybridization Buffer and 
ULTRAhyb Hybridization Buffer (Ambion) were used for oligonucleotide probes and for 
random-labeled probes, respectively, as per the manufacturer’s instructions. Oligo probes 
were labeled with [γ-32P] ATP with T4 poly-nucleotide kinase (NEB). Labeling of 
random-labeled probes was performed with the Prime-It RmT Random Primer Labeling 
Kit (Stratagene). Decade Markers were used as a ladder on small RNA northern blots 
(Ambion). ssRNA ladder was used for normal Northern blots (NEB). Blots were 
visualized and quantified with X-ray film and Image J. The oligonucleotide probe 
sequence for human mascRNA in small RNA Northern is 
AGACGCCGCAGGGATTTGAACCCCGTCCTGGAAACCAGGAGTGCCAACCACC
AGCATC; for U6 is 
GCTAATCTTCTCTGTATCGTTCCAATTTTAGTATATGTGCTGCCG; for MALAT1 in 
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normal Northern is ACGAATTCAGGGTGAGGAAGTAAAAACAGGTCATCTATTCA 
CAAAACTGA. The PCR fragment used as template to make random-labeled probe for 
TALAM1 is the 5’ RACE-Nest PCR product of TALAM1, which is described in Figure 
2.4A,C. 
2.4.15 In vivo Decay Assay 
U2OS 2-6-3 Tet-off cells were maintained in DMEM supplemented with 
10% tetracycline-approved FBS and 2 mM L-glutamine at 37 °C and 5% 
CO2(Rafalska-Metcalf et al, 2010). In vivo decay assays were modified from the 
procedure described previously (Brown et al, 2014). pCMV-EYFP (EYFP-N1, Clontech) 
or pCMV-hTALAM1 full length was transfected into U2OS 2-6-3 Tet-Off cells with 
Lipofectamine 2000, 5 hours later fresh medium was added. 24 hours after 1st 
transfection, the pTRP-βΔ1,2-MALAT1 ENE+A+mascRNA construct was 
transfected(Brown et al, 2014). After 5 hours, the medium was changed into fresh 
medium with 50ng/ml doxycycline, and the transcriptional pulse was started ~24 hours 
after transfection by washing the cells twice with PBS and adding medium 
lacking doxycycline. At the end of a ~5 hours pulse period, the medium was removed, 
and fresh medium with 50 ng/ml doxycycline was added. Cells were harvested at various 
time points, and RNA was isolated with Trizol and analyzed by RT-qPCR. Since 
βΔ1,2-MALAT1 ENE+A+mascRNA is known to undergo single decay(Brown et al, 
2014), the percentage of RNA remaining versus time were fit to a single-exponential 
decay equation: RNA remaining=A (exp(-k t)), as represented by the trendlines. The 
half-lives of reporter RNA were calculated from t1/2=ln 2/k, as described 
previously(Brown et al, 2014). qPCR primers for βΔ1,2 are b-globin-F: 
CCACTCCTGATGCTGTTATG and b-globin-R: CTCACTCAGTGTGGCAAAG. 
2.4.16 In vitro Cleavage Assay 
9×105 HeLa cells were lysed in 300μl lysis buffer containing 10mM Tris-HCl, pH 7.5, 
2.5mM MgCl2, 100mM KCl, 2mM DTT, 0.2mM PMSF, 5% Glycerol, 200U/ml RNase 
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Inhibitor and additional protease inhibitors. The cell lysate was rotated at 4oC for 10mins 
and then subject to sonication using Bioruptor Power-up (Diagenode), 5 cycles of 30” on 
+30” off at high level. Debris was pelleted by centrifuge at 10000g at 4oC for 5 mins. The 
supernatant was taken and supplemented with 0.5mM ATP, 100mM NH4Cl, 10mM 
MgCl2, 1mM 2-mercaptoethanol, and 0.01% Triton X-100 as final concentration. In vitro 
transcribed RNA was folded in presence of 6.4mM MgCl2 and diluted RNase Inhibitor, 
by incubation at 65oC for 2 mins, then slow cool down to 30oC. Substrate 32P-MALAT1, 
YFP and TALAM1 RNA fragments were folded separately. Substrate 32P-MALAT1 was 
used at ~10,000CPM, ~4fmol per 15 μl reaction system. The mole ratio of YFP or 
TALAM1 RNA fragments to substrate 32P-MALAT1 RNA was 10:1. Folded YFP or 
TALAM1 RNA fragments were first added to the cell lysate, followed immediately by 
the addition of folded substrate 32P-MALAT1 to start the reaction. The reaction was 
carried out at 30oC for indicated time. The reaction was stopped by addition of RNA 
loading dye and analyzed by a 12% Polyacrylamide/8M urea gel and exposure to X-ray 
film.  
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2.5 Figures 
 
Figure 2.1 Strand-specific RT-qPCR strategy. (A) RT-qPCR strategy without the 
application of the linker sequence, which gives nonspecific amplification that is 
independent of the RT primer and thus is not strand-specific. This is due to the inherent 
property of RTase enzyme to reverse transcribe self-primed RNA template independent of 
RT primer(Tuiskunen et al, 2010). (Aa) Schematic representation of the RT-qPCR 
strategy without the application of the linker sequence, in which a gene-specific reverse 
transcription primer without tagging (GSP-RT) was used to perform reverse transcription, 
and then a pair of gene-specific forward and reverse primers (GSP-F’ and GSP-R’) was 
used in the qPCR reaction. (Ab) Non-strand-specific amplification that is independent of 
RT primer, using MALAT1 in HeLa and HCT116 cells as an example, shown by the 
comparable qPCR signals from cDNAs reverse transcribed in presence (HeLa, HCT116) 
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Figure 2.1 (cont.) and absence of RT primer (HeLa minus RT primer, HCT116 minus RT 
primer). Absence of genomic DNA contamination was confirmed by the minus reverse 
transcriptase controls (minus RTase). (B) Schematic representation of the strand-specific 
RT-qPCR (ssRT-qPCR) strategy, in which a gene-specific reverse transcription primer 
tagged with a linker sequence (linker-GSP-RT) was used to perform reverse transcription 
(Vashist et al, 2012). A gene-specific forward primer (GSP-F’) and the linker (linker-R’) 
as reverse primer were used in the qPCR reaction, and strand-specific detection of RNA 
was shown in Figure 2.2A. 
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 Figure 2.2 TALAM1 is a NAT at the MALAT1 locus. (A) Expression analysis of 
TALAM1 and MALAT1 in various human cell types via ssRT-qPCR. The levels of 
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Figure 2.2 (cont.) TALAM1 and MALAT1 in different cell types were individually 
normalized against the levels in U2OS. (B) Schematic diagrams of TALAM1 and 
MALAT1 gene positions in human genome. (C) Upper panel: Dual RNA-FISH in HeLa 
cells using probes against the 5’ unique region of TALAM1 (green) and single molecule 
FISH probes against MALAT1 (red); Bottom panel: TALAM1 RNA-FISH (green), with 
DNA-FISH against MALAT1 (red) genomic locus (Scale bar, 5 μm). In HeLa cells DNA 
FISH targeting MALAT1 genomic loci generally showed 2-4 foci per cell, which is due to 
the presence of multiple copies of chromosome 11, harboring MALAT1 locus in these 
cells. (D) ssRT-qPCR analyses to quantify mouse Malat1 and Talam1 levels in Malat1 
Wild type (+/+), heterozygous (+/-) and homozygous (-/-) knockout primary mouse 
embryonic fibroblasts. (E) ssRT-qPCR analyses of human MALAT1 and TALAM1 levels 
in HeLa cells treated with Control-Scr, MALAT1-ASO1, and MALAT1-ASO2. Bar data 
are mean values with SD, N=3 (biological replicates, *p<0.05, **p<0.01 and ***p<0.001, 
two-tailed paired Student t-test). 
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 Figure 2.3 Copy number analysis of TALAM1, relative to MALAT1. TALAM1 full 
length plasmid DNA at predetermined concentration (107 molecules/μl) was serial diluted 
(dilution factor:5), used as template and assayed by qPCR using TALAM1 primer set 
(targeting the 5’ unique region of TALAM1, represented as DNA template_TALAM1) 
and MALAT1 primer set (targeting an overlapping region of MALAT1 and TALAM1, 
represented as DNA template_MALAT1). Standard amplification curves were generated 
by linear regression of the Ct values (Y axis) against the serial dilution times (X axis), 
represented by the trendlines and equations for TALAM1 and MALAT1, respectively.  
The RT-qPCR value from ~580 HeLa cells was determined and fit into the regression 
equation to calculate the copy number of TALAM1 relative to MALAT1 ( For MALAT1, 
1/10 of the cDNA was used, to get the Ct value in a range comparable to that of 
TALAM1 in order to minimize the biases from differences in qPCR amplification 
efficiencies). The ratio of TALAM1: MALAT1 was calculated by 10×5-(X of cDNA_TALAM1 – 
X of 1/10 of cDNA_MALAT1). 
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 Figure 2.4 RACE analyses of TALAM1 RNA. (A) Schematic representation of the 
oligonucleotides and PCR primers used in the RACE experiment. The red arrows in (B) 
and (C) point to the 3’ RACE and 5’ RACE (nested) PCR products, respectively. (See 
also Materials and Methods). NS=nonspecific. 
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 Figure 2.5 Northern blot analysis of TALAM1. (A) Schematic illustration of the probe 
used for TALAM1 Northern blot analysis. A PCR fragment containing the 963 bp 5’ 
unique region of TALAM1 and 77 bp overlapping sequence (illustrated in purple), was 
used as template to generate TALAM1 Northern probe via random-priming. (B) Northern 
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Figure 2.5 (cont.) blot of TALAM1(Ba), MALAT1 (Bb) and β actin (Bc) in HeLa. 
Prominent bands are pinpointed by red arrows. Same blot in Figure Ba was stripped and 
reprobed for MALAT1 using strand-specific probe generated via end labeling of 
MALAT1-specific antisense oligos. Note: The MALAT1 band is at the expected 7kb size, 
distinct from the TALAM1 bands, which is above 7kb. (C) Northern blot of TALAM1, 
MALAT1 and β actin in Scr and TALAM1-ASO2 treated HeLa samples. (D) Northern 
blot of TALAM1, MALAT1 and β actin in Scr and MALAT1-ASO2 treated HeLa 
samples. 
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 Figure 2.6 Further characterization of TALAM1 RNA. (A) The genomic landscape of 
human TALAM1 in UCSC genome browser. (B) TALAM1 RNA is enriched in the 
polyadenylated fraction. Poly(A) plus verse minus RNA fractionation in HeLa cells 
followed by RT-qPCR  showed the enrichment of TALAM1 in poly(A) RNA fraction. 
GAPDH and 18srRNA were used as controls to show the purity of fractionation.  
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Figure 2.6 (cont.) Note that the abundant mature form of MALAT1 also manifests a 
moderate enrichment at the poly(A) plus fraction due to its 3’ end genome-encoded 
A-rich tract. Positive values are the folds of enrichment in poly(A) plus over poly(A) 
minus, while negative values are the folds of enrichment in poly(A) minus over poly(A) 
plus.  
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 Figure 2.7 MALAT1 positively regulates the transcription and stability of TALAM1, 
and forms RNA duplex with TALAM1 in vivo. (A) Schematic diagrams depicting 
MALAT1 genomic locus. Relative positions of the primers used in ChIP experiment in (B), 
are indicated by asterisks labeled as “a” and “b”: Primer set “a” is at TALAM1 promoter, 
“b” is at upstream 4kb of TALAM1 TSS. Relative positions of the primers analyzed in 
RNase protection assay in (D), are indicated by asterisks labeled as 1 to 4. (B) 
ChIP-qPCR of RNA Pol II at TALAM1 promoter region, in HeLa cells treated with 
Control-Scr, MALAT1-ASO1 and ASO2. Primers from 4kb upstream of TALAM1 TSS, 
GAPDH and ACTB promoters were used as negative controls. (C) TALAM1 stability in 
HeLa cells treated with Scr or MALAT1-ASO2. Dotted lines represent the half-life of 
50 
 
Figure 2.7 (cont.) TALAM1. (D) In vivo RNase protection assay. HeLa cells were lysed 
in absence or presence of RNaseA, then RNA was extracted and analyzed via (Da) 
RT-qPCR and (Db) RT-PCR, using primers illustrated in (A). Data in (B) and (C) are 
mean values with SEM, NB=3 (3 technical replicates of representative biological 
replicates), NC=4; Data in (Da) is mean value with SD, N=3 (biological replicates, 
*p<0.05, **p<0.01, two-tailed paired Student t-test). 
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 Figure 2.8 TALAM1 stability in HeLa cells treated with Scr and MALAT1-ASO1. 
Dotted lines represent the half-life of TALAM1. Data plotted are mean values with SEM, 
N=3 (*p<0.05, two-tailed paired Student t-test). 
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 Figure 2.9 Species-specific rescue of TALAM1 by exogenously overexpressed 
MALAT1. (A) Rescue of human TALAM1 levels by human MALAT1 in HeLa. Empty 
vector (V) or construct expressing human MALAT1 with point-mutations conferring 
resistance to MALAT1-ASO2 knockdown (ASO2-R) was first transfected into HeLa cells. 
12 hours post transfection, cells were treated with Scr or MALAT1-ASO1 or ASO2 for 
24 hours. Then MALAT1 and TALAM1 levels were determined via ssRT-qPCR. (B) 
Inability of human MALAT1 to rescue mouse Talam1 in transformed MEF with 
53 
 
Figure 2.9 (cont.) homozygous knockout of Malat1 (Malat1-/- Tr MEF). Empty vector 
(V) or construct expressing human MALAT1 (hMALAT1-OE) was transfected into 
Malat1-/- Tr MEF, and 24 hours post transfection, human MALAT1 and mouse Talam1 
levels were determined via ssRT-qPCR. Data plotted are mean values with SD, N≥3 
(biological replicates, *p<0.05, two-tailed paired Student t-test).   
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 Figure 2.10 MALAT1 cellular accumulation and 3’ end processing are compromised 
in TALAM1-depleted cells. (A) ssRT-qPCR analyses of TALAM1 and MALAT1 levels 
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Figure 2.10 (cont.) in HeLa cells treated with Control-Scr, and two TALAM1-ASOs. (B) 
Schematic diagrams illustrating the RNA cutoff assay. Please also refer to Methods for 
details. R’ represents the adaptor sequence. Gene-specific forward primers upstream and 
downstream of the mascRNA cleavage site (cleaved-F’ and uncleaved-F’) are used to 
detect cleaved MALAT1 and uncleaved MALAT1, respectively. (C) Determination of 
uncleaved MALAT1 levels in Control-Scr and TALAM1-ASOs treated HeLa cells, using 
cutoff assay. (D) Northern blot analysis to detect mascRNA after TALAM1 knockdown. 
U6 snRNA was used as internal loading control. The reduction of mascRNA after 
TALAM1-ASO1 and ASO2 treatment was estimated by quantifying and normalizing the 
signal intensity of mascRNA to U6, via ImageJ software 
(http://rsb.info.nih.gov/ij/index.html). (E) qPCR analyses of HeLa samples treated with 
Control-2’MOE (Ctr) and MALAT1-2’MOE targeting human mascRNA site (2’MOE). 
Bar data are mean values with SD, NA=4, NC=4, ND=3 (biological replicates, *p<0.05, 
**p<0.01, two-tailed paired Student t-test). 
 
 
 
 
 
 
 
 
 
56 
 
 Figure 2.11 Lower concentrations of TALAM1-ASOs show similar effects on 
MALAT1 as higher concentration treatment. RT-qPCR analyses of RNA extracted 
from HeLa cells treated with lower concentration of Scr, TALAM1-ASO1 and ASO2 at 
50nM, for two rounds of knockdown. Data plotted are mean values with SD, N≥3 
(biological replicates, *p<0.05, **p<0.01and ***p<0.001, two-tailed paired Student 
t-test). 
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Figure 2.12 TALAM1 overexpression is not sufficient to alter total levels of 
MALAT1 RNA. ssRT-qPCR analyses of TALAM1 and total MALAT1 levels in HeLa 
cells transfected with empty vector (V) or with TALAM1-overexpression construct 
(TALAM1-OE). Data plotted are mean values with SD, N=4(biological replicates, 
*p<0.05, two-tailed paired Student t-test). 
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 Figure 2.13 TALAM1 promotes the 3’ end processing of MALAT1 RNA. (A) Cutoff 
assay of cleaved and uncleaved MALAT1 in HeLa cells transfected with empty vector (V) 
59 
 
Figure 2.13 (cont.) or with TALAM1-overexpression construct (TALAM1-OE). (B) 
Analyses of mascRNA levels in V or TALAM1-OE samples by (Ba) Northern blot, and 
(Bb) Taqman small RNA assay. (C) In vivo RNA decay assay. (Ca) Schematic 
representation of the βΔ1,2 construct. (Cb) Stability of the intronless β-globin transcript 
in U2OS Tet-off cells transfected with empty vector (V) or with 
TALAM1-overexpression construct (TALAM1-OE). Trendlines are single-exponential 
regression of the percentage of RNA remaining versus time. Dotted lines represent the 
half-life of reporter RNA.  (D) In vitro processing assay of MALAT1 3’ end sequence. 
Internally 32P-labeled MALAT1 ENE+A+mascRNA RNA substrate (filled arrow in Db) 
was incubated with HeLa total cell extract in absence or presence of in vitro transcribed 
YFP, TALAM1-F1R1, F2R2 RNA or 2’MOE targeting the mascRNA site, and its 
processing to mascRNA (open arrow in Db) is monitored at 40mins and 60mins time 
points. (Da) Schematic diagrams shown for the relative positions of the TALAM1-F1R1 
and TALAM1-F2R2 fragments generated by in vitro transcription. (Db) A representative 
autoadiogram is shown. (Dc) The quantification of the mascRNA product levels 
measured from independent experiments, with ImageJ software. At 40mins time point, 
levels of mascRNA produced under different conditions were normalized to the condition 
with no extra RNA, which was set as one. Bar data in (A) and (Bb) are mean values with 
SD, NA=4, NBb=3; Data in (Cb) and (Dc) are mean values with SEM, NCb=4, 
NDc=6(biological replicates, *p<0.05, **p<0.01, two-tailed paired Student t-test). 
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Figure 2.14 Replicates of the in vitro processing assay of MALAT1 3’ end sequence. 
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 Figure 2.15 NAT is also present at MENβ locus. (A) ssRT-PCR was applied to analyze 
the presence of NAT at the 3’ end of MENβ. Linker tagged RT primer with sequence 
same to the strand of MENβ, starting from 49bp downstream of MENβ’s 3’ end, was used 
to reverse transcribe any potential NATs of MENβ from HeLa total RNA. Then PCR was 
performed using the linker sequence as forward primer, and primer at position +326 as 
reverse primer for the 1st PCR, and primer at position +129 as reverse primer for the nest 
PCR. The NAT was amplified in 1st PCR (Ba) with smear. The smear product (dashed 
rectangle) was cut out and confirmed by sequencing as well as nested PCR (Bb, pointed 
by arrow). 
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 Figure 2.16 Model for the feed-forward positive regulatory loop at the MALAT1 
locus to maintain the high cellular levels of MALAT1.  
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CHAPTER 3. LONG NONCODING RNA S7 REGULATES CELL CYCLE 
PROGRESSION BY MODULATING THE HIPPO PATHWAY 
3.1 Introduction 
Proper regulation of cell division cycle is crucial to the growth and development of all 
organisms. Understanding this regulation is central to the study of many diseases, most 
notably cancer. Massive transcriptional changes accompany the entire cell division 
process. Extensive studies on the identification of protein coding genes exhibiting 
periodical expression patterns have led to the great progress in our understanding of the 
basic cell cycle process and its regulatory mechanism, exemplified by studies on cyclins 
(Pines & Hunter, 1989). Moreover, many of the cell cycle-regulated protein coding genes 
have later been found to aberrantly-expressed in cancer cells (Whitfield et al, 2002). 
Therefore, characterization of the genome-wide transcriptional program during the cell 
cycle is a critical step towards a deeper understanding of the cell proliferation process and 
its role in cancer.   
One of the most unexpected discoveries in the genomics era of biology is the extensive 
transcription of RNA from non-protein-coding regions of the genome. Tens of thousands 
of long noncoding RNAs (lncRNAs), defined as transcripts larger than 200nt with no 
protein-coding potential, have been identified in mammalian cells (Djebali et al, 2012; 
Harrow et al, 2012). Pioneer studies on a small proportion of lncRNAs revealed that 
lncRNAs are an integral part of the cellular control network that co-exists along with 
proteins. Mechanistically, the RNA sequence and structure offer lncRNAs two inherent 
functional properties: 1) sequence-mediated interaction with genomic DNA or other RNA, 
and 2) secondary/tertiary structure-mediated interaction with RNA-binding proteins. With 
these properties, lncRNAs have been shown to modulate the recruitment of transcription 
factors, cofactors or chromatin modifiers to specific genomic locus, to regulate gene 
expression transcriptionally or epigenetically; or to regulate the binding of RNA 
processing factors or microRNAs to pre-mRNAs or mature mRNAs, thereby influencing 
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gene expression at post-transcriptional level(Batista & Chang, 2013). Functionally, 
lncRNAs have been shown to modulate diverse biological processes, including dosage 
compensation, genomic imprinting, cell metabolism, differentiation and stem cell 
pluripotency (Wang & Chang, 2011).  
Recently, several lncRNAs have been identified that regulate cell proliferation and 
viability (Schmitt & Chang, 2016). One emerging theme is the harnessment of 
transcription factors, crucial for proliferation by lncRNAs in driving cell cycle 
progression.  For example, multiple lncRNAs, including PVT1, CARLo-5, PCAT-1 and 
MY, activate Myc’s expression in cis, or potentiate Myc’s regulation of downstream 
targets in Myc-driven cancers (Kawasaki et al, 2016; Schmitt & Chang, 2016). In 
addition to Myc, the expression of E2F genes, which are critical for G1/S progression and 
B-Myb, which is important for G2/M progression are regulated by lncRNAs, including 
MALAT1(Sun et al, 2015; Tripathi et al, 2013; Yang et al, 2011b). Several lncRNAs, 
such as LUNAR1, PCGEM1, PRNCR1 and CTBP1-AS, are found to regulate the 
expression of chemokine and hormone receptors and also mediate their downstream 
transcriptional regulation functions (Schmitt & Chang, 2016). Besides, lncRNAs like 
p15-AS, lincRNA-p21, RoR, PANDA, DINO and NORAD are known to regulate cell 
cycle progression through modulating the tumor-suppressor and growth-arrest pathways 
during senescence and in response to DNA damage (Lee et al, 2016; Petermann et al, 
2010; Schmitt et al, 2016; Zhang et al, 2013). Very recently, CONCR, a lncRNA whose 
expression is periodic in cell cycle, was shown to control sister chromatid cohesion by 
directly interacting with DDX11 helicase and regulating its activity (Marchese et al, 
2016). Collectively, these reports support the significance of lncRNAs in cell cycle 
progression. Therefore, it is possible that a comprehensive characterization of the 
expression of lncRNAs during cell cycle would generate a rich resource for 
understanding the lncRNA regulatory networks that contribute to cell cycle progression.  
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In addition, such a data would provide insights into how lncRNAs are exploited by 
tumorigenic mutations that drive malignancy.  
In the present study, we systematically profiled the expression of ~17,000 curated human 
lncRNAs during cell cycle and identified 422 novel lncRNAs that display periodic 
non-random expression peaking at specific phases of the cell cycle. Functional studies of 
an S phase-upregulated lncRNA S7, revealed its important role in modulating the Hippo 
signaling pathway and thereby regulating cell cycle progression.  
3.2 Results 
3.2.1 LncRNA S7 is an S-phase upregulated and DNA damage-induced lncRNA 
To systematically discover functional lncRNAs during cell cycle, we applied an lncRNA 
microarray that interrogates ~17,000 curated human lncRNAs, including intragenic and 
intergenic as well as potential enhancer lncRNAs. Total poly (A)+ RNA prepared from 
U2OS cells synchronized at G1, G1/S boundary, S, G2 and M phases of cell cycle, were 
hybridized to the lncRNA microarray. 422 novel lncRNAs were identified to display 
phase-specific expression pattern, which show enhanced expression (>2-fold) within a 
specific cell cycle stage (100 lncRNA in G1 phase; 11 in G1/S; 100 in S phase and 200 in 
M phase) (Figure 3.1A). Based on the ENCODE information regarding (i) conservation, 
(ii) relative position to known protein-coding genes and known ncRNAs (including 
snoRNAs and microRNA host genes), (iii) RNA-Seq based transcription level data, and 
(iv) DNA and histone modifications, suggesting active RNA Pol II transcriptional 
regulation and enhancer elements (such as H3K4me1, H3K4me3, H3K27Ac, 
genome-wide transcription factor ChIP-seq data, DNase Hypersensitve sites and CpG 
islands), we identified 44/422 lncRNAs as promising candidates with potentially 
interesting functions in cell cycle progression. Two sets of qPCR primers from different 
regions of each lncRNAs were designed and tested to confirm the phase-specific  
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expression pattern. Finally, as part of my thesis research one S phase-upregulated long 
intergenic lncRNAs (lincRNAs), named as S7, was chosen for mechanistic studies 
(Figure 3.1B).  
S7, previously annotated as AK124080, is a 2 kb lincRNA. Analysis of S7 in UCSC 
(University of Santa-Cruz) genome browser revealed that, like most other annotated 
human lncRNAs, S7 is not well conserved in its gene body; however, its promoter region 
is highly conserved across vertebrates (Figure 3.1C). Its promoter region, which harbors a 
CpG island, contains high levels of H3K4me1, H3K4me3 and H3K27Ac marks together 
with high stacks of transcription factors ChIP signals, suggesting S7 is subject to active 
transcriptional regulation. Transcriptional level analysis via RNA-seq in 9 human cell 
lines revealed S7 is present at low abundance in most of the cell lines tested, but has a 
high expression in H1-ESC. Estimation of protein-coding potential using PhyloCSF 
revealed no coding potential along the entire region of S7 locus (Figure 3.1C). RNA 
fractionation using Oligo-dT columns followed by RT-qPCR analysis confirmed S7 to be 
a polyadenylated transcript (Figure 3.1D).  
S-phase of cell cycle is an intrinsically challenging phase for cells, given that any trouble 
during DNA replication could give rise to DNA damage and elicit DNA damage response 
(DDR). The S-phase upregulation of S7 promoted us to investigate whether DNA damage 
can also induce S7 expression. Cells treated with doxorubicin, (which intercalates DNA 
and inhibits topoisomerase II), or Etoposide (another topoisomerase II inhibitor) showed 
induction of S7 (Figure 3.1Ea). In addition, cells treated with hydroxyurea (HU; 2mM)) 
for 24 hrs, a condition that produced double strand breaks by inducing the collapse of 
replication fork (Petermann et al, 2010), also showed induction of S7 (Figure 3.1Ea). 
Several lncRNAs have been involved in p53-mediated stress response, and their 
induction upon DNA damage is dependent on the integrity of the p53 pathway (Huarte et 
al, 2010; Hung et al, 2011). To address whether S7 falls into this group, we used the 
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isogenic WT and p53 -/-  KO (knock-out) HCT116 cells, and observed similar extent of 
induction of S7 after Etoposide treatment in both p53 WT and KO cells (Figure 3.1Eb), 
indicating that S7 is a novel lncRNA that is induced upon DNA damage independently of 
p53. By single molecular RNA FISH (smFISH), we observed that S7 lncRNA is located 
both in nucleus and in cytoplasm (Figure 3.1Ec). In addition, cells treated with 
doxorubicin increased levels of S7 smFISH foci, especially in the cytoplasm (Figure 
3.1Ec). Even though S7 sequence is not well conserved across vertebrates (Figure 3.1C), 
we were able to identify the mouse homolog of S7 based on genomic synteny and 
sequence similarity. Interestingly, mS7 levels were elevated in mouse embryonic 
fibroblasts (MEFs) that were incubated with Etoposide (Figure 3.1F). Together, these data 
suggest S7 is a novel lincRNA that is upregulated in S-phase of the cell cycle and during 
DDR, in a p53-independent and evolutionary conserved manner.  
3.2.2 Depletion of S7 results in defects in cell cycle progression 
To address the functional significance of the S-phase upregulation of S7, we addressed 
whether S7 is required for normal cell cycle progression. We obtained siRNAs targeting 
different regions of S7, and U2OS cells depleted of S7 using these siRNAs showed 
defects in S-phase entry, as observed by G1 or G1/S arrest with a concomitant reduction 
in S-phase population (Figure 3.2A). We verified this phenotype in other cell types, 
including the pseudo-diploid HCT116 cells (Figure 3.2Ba), suggesting this is not a cell 
type specific phenotype, but rather S7 maybe generally required for normal S-phase 
progression. Further, we generated S7 knock out cells in both HCT116 and U2OS cells 
by utilizing CRISPR/Cas9 technology (Figure 3.2Ca). We observed that independent 
clones of S7 knockout lines displayed G1 or G1/S arrest similar to S7 knockdown cells 
(Figure 3.2Cb), further supporting the role of S7 lncRNA in S-phase progression. We also 
tested the S7 knockdown phenotype in HCT116 p53-/- line, and observed S7-depleted 
cells arrested at G2/M phases, instead of G1 or G1/S phase (Figure 3.2Bb). This result 
indicates that G1 or G1/S arrest observed in S7-depleted cells require an intact p53, 
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implying S7-depleted cells elicit intra-G1 or G1/S check-point mediated by p53. In 
support of this, we observed activation p53 and p21 in S7-depleted cells (Figure 3.2D).    
To identify the cause of cell cycle arrest and p53 induction in S7-depleted cells, we 
determined whether there is increased endogenous DNA damage happening in 
S7-depleted cells, which then could lead to the activation of p53-mediated G1 or G1/S 
checkpoints. We performed Comet assay to access the cellular level of DNA damage, and 
found that S7-depleted cells showed significanct increase in the levels of DNA damage 
(Figure 3.2E). In addition, S7-depleted cells showed defects in the chromatin loading of 
pre-replication complex (pre-RC), such as MCMs (Figure 3.2F). These data imply that S7 
plays important roles in DNA replication and normal cell cycle progression, and its 
depletion results in increased endogenous DNA damage and activation of cell cycle 
checkpoint.  
3.2.3 Depletion of S7 leads to defects in DDR and hypersensitivity to DNA damage 
Given that S7 is upregulated during S phase and strongly induced upon DNA damage and 
upon replication stress (Figure 3.1B, 3.1E), and loss of S7 leads to cell cycle arrest with 
more endogenous DNA damage and activation of cell cycle checkpoints, we reasoned 
that S7 maybe involved in sensing and/or repairing DNA damages that are generated 
during replication. To test this hypothesis, we treated cells with HU for 24 hours, which 
represents a strong replication stress by causing the collapse of replication 
forks(Petermann et al, 2010), and analyzed the recovery of cells after release in presence 
or absence of S7. By PI flow cytometry, we observed that control cells that are released 
post HU treatment resumed DNA replication quickly, and majority of these cells reached 
G2/M phase by 12 hours post- HU-release (Figure 3.3A). However, S7-depleted cells 
showed defects in S-phase progression, as observed by the accumulation of a significant 
fraction of S7-depleted cells in S-phase in cells that were released for 12hrs post-HU 
treatment (Figure 3.3A). By 24 hours post-release, we continued to observe a 
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significantly larger population of cells that were stuck in S-phase in S7-depleted sample 
compared to control cells (Figure 3.3A). The observed phenotype could be due to 
multiple reasons, including defects in DNA replication fork initiation or progression 
during S-phase. To test this, we performed DNA fiber combing assay. Control and 
S7-depleted cells were first incubated with Thymidine analog CIdU for 30 minutes to 
label the replicating DNA strands. CIdU was then washed off, and cells were treated with 
HU for 24 hours to induce replication fork collapse and double strand breaks. Then cells 
were released into medium containing another Thymidine analog IdU for 30 minutes. In 
this way, the newly synthesizing DNA strands will be labeled with IdU. DNA Fiber assay 
revealed that S7-depleted cells showed reduced number of new replication origins 
(Figure 3.3Ba-b). At the same time, both control and S7-depleted cells showed 
comparable length in the CldU and IdU-lablled fibers, indicating normal replication fork 
progression (Figure 3.3Bc). Based on the results from DNA fiber assay, we conclude that 
defects in the S-phase progression observed in S7-depleted post-HU released cells is due 
to inefficient firing of new origins. This result is consistent with our earlier results 
showing elevated levels of S7 in G1/S and early S-phase cells, and depletion of S7 
resulted in G1 or G1/S arrest and defects in the chromatin loading of MCM complex.  
In addition to defects in S-phase progression, S7-depelted post HU-released cells also 
failed to activate some of the key DNA damage checkpoint responses. For example, 
S7-depleted post-HU-released cells showed reduced Chk1 phosphorylation at Ser345, 
BRCA1 phosphorylation at Ser1524, RPA32 phosphorylation and induction of γH2AX 
(Figure 3.3C). To further address the physiological impact of S7 on cell viability and 
survival, we performed MTT assay and clonogenic assay (to assess short term cell 
viability and long-term cell survival, respectively) in control and S7-depleted cells. Under 
normal growth conditions, S7 depletion lead to compromised cell viability and long-term 
survival (Figure 3.3D, 3.3E, compare NC_Ctr with si7b_Ctr), supporting our previous 
results showing defects in cell cycle progression upon S7 depletion (Figure 3.2). After 
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DNA damage using low dose of Doxorubicin, S7-depleted cells showed more reduction 
in cell viability and survival compared to control Doxorubicin-treated cells (Figure 3.3D, 
3.3E), and the difference in cell viability and cell survival observed between NC_Dox 
and si7b_Dox was more significant than the differences observed between NC_Ctr and 
si7b_Ctr cells, implying that besides the defects in cell proliferation and viability, S7 
depletion causes additional sensitization to DNA damage and defects in DNA damage 
recovery (Figure 3.3A, 3.3B, 3.3C). Together, these data revealed that S7-depleted cells 
are more sensitive to drug-induced DNA damage, implying that S7 lncRNA is involved in 
DDR, and its loss causes defects in cells’ ability to recover from DNA damage. 
3.2.4 S7 regulates the expression of genes involved in cell proliferation and DDR in 
cis 
In order to understand the underlying molecular mechanism through which S7 lncRNA 
regulates cell cycle and DDR we analyzed the changes in the steady state mRNA levels in 
control and S7-depleted cells utilizing transcriptome microarray. To determine the 
primary effect of S7 depletion, out of the secondary effect of cell cycle arrest, we 
collected control and S7 siRNA treated cells at early and late time points (24 and 48 hrs 
post siRNA treatment). Cells collected at early time point, though showed efficient 
depletion of S7, did not show any observable cell cycle defect phenotype, assessed by 
flow cytometry analyses. On the other hand, late time point cells showed cell cycle arrest 
(Figure 3.4A). To identify the genes that are affected during DDR, we also collected 
siRNA treated cells after Doxorubicin treatment (Figure 3.4A). To identify direct target 
genes of S7, we looked for common targets the expression of which are altered in both 
early and late time points. Gene ontology (GO) analyses from both early and late time 
point microarray data set indicated that S7-depleted cells affected the expression of genes 
involved in Cellular Growth and Proliferation, Cell Death and Survival (Figure 3.4B). 
Since, early time point cells did not show any observable defects in cell proliferation, but 
at the same time showed reduced expression of genes involved in cell proliferation and 
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growth, we suggest that some of these genes could be direct targets of S7 and the reduced 
expression of these genes in S7-depleted cells resulted in cell cycle defect.    
S7 lncRNA is a low abundant transcript (based on RNA-seq analyses and smFISH) 
(Figure 3.1C, 3.1Ec). We hypothesized that like other low abundant lncRNAs, S7 might 
be functioning in cis, via regulating nearby protein coding genes at close genomic 
proximity (Wang & Chang, 2011), through which its gene regulatory effect could be 
amplified. To test this hypothesis, we looked at the microarray data set to assess mRNA 
levels of several genes that are located near S7 gene locus, both at the early and late time 
points. Interestingly, several but not all genes closely surrounding S7 locus, showed 
significant downregulation upon S7 depletion. Using qRT-PCR, we validated the changes 
in mRNA levels of these gens upon S7-depletion by using two independent siRNAs 
(Figure 3.4C). Quite interestingly, several of the cis-downregulated genes were known to 
be involved in DNA replication, cell proliferation, oncogenic transformation and DDR. 
For example, GADD45B is involved in DDR (Salvador et al, 2013), MYADM is required 
for colony formation in bone marrow cells (Pettersson et al, 2000), and PLEKHG2 is a 
transforming oncogene with exchange activity for CDC42 (Sato et al, 2014; Shain et al, 
2013). Moreover, WTIP (Wilms tumor-interacting protein), located ~600kb downstream 
of S7 gene, which is an ortholog of Ajuba in Drosophila that is known to positively 
regulate YAP1 activity and thereby promotes cell proliferation, was also downregulated 
in S7-depleted cells (Figure 3.4C). Transcription from lncRNA gene loci is known to alter 
local chromatin architecture, thereby positively or negatively regulating transcription of 
nearby protein-coding genes. To address whether S7 regulates the expression of the 
nearby genes, we examined the expression of several genes that are located near S7 and 
WTIP gene loci in control and S7-depleted cells. Out of six genes that we tested, only 
WTIP showed consistent downregulation in S7-depleted cells, indicating that S7 does not 
influence the expression of most of the nearby located genes, but specifically modulate 
the expression of genes such as WTIP (Figure 3.4D). Together, these data suggest that S7 
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specifically regulates the expression of a group of cis genes, which are involved in cell 
proliferation and DDR.  
3.2.5 WTIP is one of the cis targets of S7, through which S7 represses Hippo 
signaling and promotes cell proliferation 
WTIP is a member of the mammalian Ajuba LIM family proteins, along with Ajuba and 
LIMD1. Ajuba LIM family proteins are adaptor proteins that communicate cell adhesive 
events with nuclear responses to antagonize the inhibitory phosphorylation of YAP and 
negatively regulate Hippo signaling pathway (Das Thakur et al, 2010; Harvey et al, 2013). 
Mechanistically, Ajuba LIM proteins interact with kinases LATS and SAV to inhibit their 
phosphorylation of YAP. LATS and SAV-mediated phosphorylation of YAP decreases the 
stability of YAP and prevents it from accumulating in the nucleus (Zhao et al, 2010a). 
Therefore, the presence of Ajuba LIM proteins ensures the nuclear accumulation of YAP 
where it acts as an important pro-growth transcription cofactor by collaborating with 
transcription factors including TEADs and Fos(Harvey et al, 2013).  
Given this crucial role of WTIP in regulating YAP and Hippo signaling, we hypothesized 
that WTIP could be an important cis target of S7, mediating S7’s positive effect on cell 
cycle progression. To test this, we examined whether S7-depleted cells, where there is 
reduced WTIP level, also displayed downregulation of known YAP1 targets. CCND1 and 
CTGF are the two most well-established targets of YAP1 (Harvey et al, 2013; Zhao et al, 
2008a), and we found that both these genes were significantly downregulated in 
S7-depleted cells (Figure 3.5Aa, left panel). Since CCND1 expression is also regulated 
by other pathways, including E2Fs, whose activity is cell cycle regulated, we tested the 
levels of other E2F targets (CDT1, E2F3 and MCM6) in S7-depleted cells, and observed 
no significant changes, suggesting that the downregulation of CCND1 was not due to 
secondary effects of G1 cell cycle arrest or due to defects in E2F transcription activity 
(Figure 3.5Aa, right panel).  In addition, we also observed downregulation of WTIP, 
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YAP and CCND1 in HCT116 p53-/- cells after S7 depletion, where S7 depletion causes 
G2/M but not G1 arrest, further supporting that the downregulation of CCND1 in 
S7-depleted cells is not a consequence of G1 arrest (Figure 3.5Ab). By performing 
western blot analyses in total cellular extracts we confirmed reduced levels of WTIP, 
CCND1 and YAP proteins in S7-depleted cells (Figure 3.5B). Finally, by performing 
RT-qPCR we observed repression of significant number of YAP1 targets in S7-depleted 
samples (Figure 3.5C). To dissect out the perturbations on YAP1 targets by other 
pathways, and to directly assess the YAP1 pathway activity, we employed a reporter 
system where the promoter of CTGF was cloned into a basic luciferase reporter. In 
addition to the reporter with wild type CTGF promoter, a mutant reporter with 
TEAD-binding sites mutated in the CTGF promoter was also used to reflect the 
transcriptional activity contributed by other pathways apart from the WTIP-TEAD 
axis(Zhao et al, 2008a). We transfected these wild type and mutant reporters into U2OS 
cells pre-treated with NC or S7 siRNAs, and monitored the reporter activities by 
luciferase assay. We observed that in NC-treated control cells, the luciferase activity of 
wild type reporter is much higher than that of TEAD-mutant reporter, indicating that in 
U2OS cells, the majority of transcriptional activity of the reporter is controlled by TEAD 
transcription factors (Figure 3.5D). Next, we looked at the transcription activity of 
reporter in S7-depleted cells. Interestingly, S7-depleted cells showed a significant 
decrease in the reporter activity, implying that S7 influences TEAD activity through 
regulating WTIP-YAP1 axis (Figure 3.5D).    
To determine the role of WTIP in mediating S7’s functions, we performed knockdown of 
WTIP using siRNA (Figure 3.5E). Upon WTIP knockdown, we observed downregulation 
of YAP1, CCND1 and p15PAF (Figure 3.5F). Further, WTIP-depleted cells showed 
enhanced G1 arrest with a concomittent decrease in S-phase population. These 
phenotypes were further confirmed using a different set of siRNA targeting WTIP, that is, 
smartpool siRNAs (Figure 3.5H, 3.5I). In general, phenotypes observed in 
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WTIP-depleted cells phenocopy the phenotypes in S7-depleted cells, arguing that S7 acts 
upstream of WTIP in the YAP1-HIPPO signaling pathway.  
3.2.6 S7 promotes WTIP transcription through interacting with DDX5 
LncRNAs regulate the transcription of protein-coding genes or post-transcriptional 
processing of their transcripts. We performed nascent RNA capture analyses followed by 
RT-qPCR to determine the involvement of S7 in transcription regulation of WTIP. During 
a 30 minutes pulse period, EU (an Uridine paralog) was added to cell medium, so all 
nascent RNAs produced during this period was labeled by EU, allowing the EU-labeled 
RNAs to be isolated by EU-specific affinity purification. Then qRT-PCR was performed 
on these captured nascent RNAs to determine the abundance of nascent transcripts of 
interest. S7-depleted cells, showed significant reduction in the levels of nascent WTIP 
pre-mRNA (Figure 3.6A). These results indicate that S7 depletion compromised the 
transcription of WTIP. p21, which is induced upon S7 depletion by the p53-mediated G1 
checkpoint, was used as a positive control of the experiment.  
In general, lncRNAs regulate the expression of nearby genes by facilitating the 
recruitment or stabilization of transcription factors or co-factors or chromatin regulators 
or RNA-binding proteins. In order to understand the molecular mechanism utilized by S7 
to control the transcription of WTIP, we looked for S7-ineracting proteins that participate 
in the transcription of WTIP. For this, in vitro transcribed biotinylated-S7 RNA was 
incubated with cell lysate and S7-interacting proteins were pulled down by streptavidin 
affinity purification followed by mass spectrometry analysis. Biotin-labeled YFP RNA 
was used as negative control. We identified several proteins that specifically interacted 
with S7 and not with YFP mRNA. We focused on the interaction between S7 and one of 
its interactors, DDX5, and its role in regulating the expression of WTIP. DDX5 was 
identified as a specific interactor of S7 RNA, as confirmed by western blot analysis 
(Figure 3.6B). RNA-Immunoprecipitation (RIP) using antibody against DDX5 followed 
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by RT-qPCR analysis further validated the endogenous interaction of DDX5 with S7 
RNA (Figure 3.6C). DDX5 is an ATP-dependent RNA helicase, but is also known to act 
as a transcriptional co-factor of several proliferation promoting transcription factors 
(Fuller-Pace, 2013). For example, DDX5 has been reported to act as a transcriptional 
co-activator of E2F1 and p53 to regulate cell cycle progression and DNA damage 
response, respectively (Mazurek et al, 2012; Nicol et al, 2013). Very recently, a role of 
lncRNA in modulating DDX5’s function has been reported in mouse T helper 17 (TH17) 
lymphocytes.  In this study, lncRNA Rmrp binds to DDX5 and facilitates the association 
of DDX5 with RORγt, a ligand-regulated nuclear receptor, and coactivates the 
transcription of selective set of TH17 genes (Huang et al, 2015). This supports the notion 
that lncRNAs could regulate the recruitment or stabilization of DDX5 to specific gene 
promoters. To determine whether DDX5 act as a transcription co-activator to regulate 
WTIP transcription, we first performed DDX5-ChIP experiment to determine the 
association of DDX5 to WTIP promoter.  We observed selective enrichment of DDX5 at 
the 5’ end of WTIP gene, including its promoter region and 1st intron region (Figure 
3.6D). Next, to further determine whether DDX5 indeed participates in the transcription 
of WTIP, we depleted DDX5 using siRNA, and we observed downregulation of WTIP at 
the RNA level (Figure 3.6E). These data together indicate that S7 interacts with DDX5, 
which acts as a transcription co-activator of WTIP by binding to its promoter region and 
promotes its transcription.  
3.2.7 S7 contributes to tumorigenicity under in vitro and in vivo conditions 
Since YAP1 is well known for its role as an oncogene, and WTIP is one of the three 
AJUBA members in human cells, which positively regulates the activity of YAP1, we 
reasoned that S7 that facilitates cell proliferation and is required for WTIP transcription, 
may also be involved in tumorigenesis. To determine S7’s involvement in tumorigenesis 
in vitro, we performed soft agar colony formation assay to assess the ability of 
anchorage-independent growth of wild type and S7-knockout HCT116 cells. In contrast 
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to wild type HCT116 cells, which is highly tumorigenic with great capability of 
anchorage-independent growth in soft agar, S7-KO HCT116 cells significantly lost their 
ability to form colonies in soft agar, revealing the requirement of S7 in the tumorigenicity 
of HCT116 cells in vitro (Figure 3.7Aa-b). We next performed tumor xenograft 
experiment to examine the in vivo effect of S7 deletion on primary tumor growth. Control 
and S7-KO HCT116 cells were injected sub-cutaneously into immune compromised mice, 
and the tumor sizes after injection was monitored for 25-30 days. We observed that the 
tumor growth in S7-KO cells to be significantly compromised compared to wild type 
HCT116 cells (Figure 3.7B), suggesting an essential role of S7 in tumorigenesis in vivo.   
Next, we were interested to determine whether S7 contributes to cancer in patients. From 
the genome copy number data of protein-coding genes, obtained from patients of 56 
cancer subtypes, we found the two protein coding genes surrounding S7, KCTD15 and 
LSM14A are frequently amplified in ~20 types of cancers, and the cancer types with high 
amplification frequency for these two genes correlate with each other, suggesting that this 
genome segment, containing S7 locus, is likely to be frequently amplified in cancers 
(Figure 3.7C). Finally, we analyzed the correlation of S7 expression level in patient tumor 
samples with patients’ survival data (Figure 3.7D). We used colon adenocarcinoma as an 
example, based on our in vitro data gained from HCT116 cells, which is derived from 
colorectal cancer. We found patients with higher S7 expression had a significantly shorter 
survival compared to patients with lower S7 expression, indicating that high S7 RNA 
level is associated with poor prognosis in colon adenocarcinoma.  
3.3 Discussion 
In this study, we performed a comprehensive analysis of human lncRNA expression 
during cell cycle. We identified hundreds of lncRNAs with periodic expression pattern 
peaking at specific cell cycle stages, and characterized the function of S7, one S 
phase-enriched lncRNA in regulating cell cycle progression. Our data suggest that S7 
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plays important roles in regulating cell cycle progression and DNA damage response. S7 
regulates a group of genes involved in cell proliferation and DDR in cis, among which is 
WTIP, a member of AJUBA family proteins that represses Hippo signaling pathway. The 
fact that depletion of WTIP largely phenocopies the cell cycle defect caused by S7 
depletion suggests that WTIP is one of the major functional targets of S7. Furthermore, 
our data support the notion that S7 regulates WTIP transcription by associating with 
DDX5 and facilitates its binding to the WTIP gene promoter to activate WTIP 
transcription, which in turn promotes cell proliferation.  
DDX5 is one of the founding members of the DEAD box family. It is an established RNA 
helicase involved in multiple processes of RNA metabolism including pre-mRNA 
splicing, rRNA processing and miRNA processing (Fuller-Pace, 2013). In addition to its 
established role as an RNA helicase, it is becoming increasingly clear that DDX5 also 
acts as transcription co-activator or co-repressor in a context-dependent manner via 
interacting with different transcription factors (Fuller-Pace, 2013). For example, in 
response to DNA damage, it interacts with and co-activates p53 to mediate cell cycle 
arrest (Nicol et al, 2013). However, during normal cell cycle progression, DDX5 was 
shown to act as a co-activator of E2F1 and stimulate the transcription of E2F1-regulated 
DNA replication factors, thereby promoting the proliferation of cancer cells (Mazurek et 
al, 2012). Although we cannot exclude that S7 has additional function, our results imply 
that the regulation of WTIP transcription by S7 may occur through S7’s involvement in 
recruiting DDX5 to WTIP promoter. We show that S7 interacts with DDX5, and DDX5 
interacts with the promoter region of WTIP gene. Importantly, depletion of DDX5 results 
in downregulation of WTIP mRNA level, suggesting that DDX5 might act as a 
transcriptional co-activator to regulate the transcription of WTIP.  
Future studies will address whether S7 controls the binding of DDX5 to WTIP promoter, 
and whether S7 is directly involved in the recruitment of DDX5 to WTIP promoter. For 
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the potential direct role of S7 in recruiting DDX5 to WTIP promoter, it is possible that S7 
RNA is present in a complex with DDX5 at WTIP promoter, and the presence of S7 
lncRNA may either confer specificity in targeting DDX5 to WTIP promoter, and/or 
stimulate the transcriptional co-activator activity of DDX5. Supporting this notion, it was 
recently reported that in mouse TH17 lymphocytes, lncRNA Rmrp binds directly to 
DDX5 and promotes the assembly of RORγt-DDX5 transcription activator complex at 
RORγt target loci, and activate the transcription of selective TH17 genes(Huang et al, 
2015). In addition, a recent study showed that a lncRNA CONCR interacts with DDX11, 
which is another member of the DEAD box family and act as a DNA helicase, and 
regulates its enzymativc activity (Marchese et al, 2016). We therefore speculate that the 
mode of action of S7 may represent a more widely spread mechanism in which lncRNAs 
interacts with the DEAD box family DNA/RNA helicases to modulate their location and 
activity.     
The Hippo pathway controls organ size and tissue homeostasis in diverse species through 
regulating cell proliferation, apoptosis and stemness, whereas the deregulation of this 
pathway contributes to tumor progression in model organisms and occurs in a broad 
range of human carcinomas. Despite the fact that Hippo pathway activity is frequently 
deregulated in different human cancers, somatic or germline mutations in Hippo pathway 
genes are uncommon (Harvey et al, 2013; Yu et al, 2015). Here, by identifying lncRNA 
S7 as a cis activator of WTIP, which is a member of AJUBA family that positively 
regulates YAP1, we hypothesize S7 acts as a potential oncogene via inhibiting the Hippo 
pathway. This hypothesis is supported by the observation that S7 genomic locus is 
frequently amplified in various cancers, and elevated expression of S7 correlates with 
poor prognosis in colon adenocarcinoma. Further in vitro and in vivo tumor assays 
revealed that S7 is required for the tumorigenicity of HCT116 cell lines. We have 
uncovered a cell cycle-regulayed lncRNA that acts as an inhibitor of Hippo pathway, and  
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its aberrant upregulation may underlie the malignancy of those cancers where S7 genomic 
locus is amplified.  
lncRNAs have been reported to participate in diverse biological processes(Wang & 
Chang, 2011). Although a recent study reported a group of ncRNAs that are transcribed 
from the promoters of cell-cycle protein genes and have coordinated transcription to their 
respective protein coding genes (Hung et al, 2011), no genome-wide unbiased lncRNA 
transcriptome analysis has been performed to identify cell cycle-regulated lncRNAs. 
Future characterization of the other cell cycle-regulated lncRNAs identified in our study 
may reveal additional lncRNAs that are important for cell cycle regulation and cancer 
development.   
3.4 Materials and methods 
3.4.1 Cell synchronization 
U2OS cells were synchronized to mitosis by treatment with 50 ng/ml Nocodazole for 
12-16 hr. To synchronize cells in G1, the mitotic cells were washed with PBS and grown 
in fresh medium for 2.5 hr. The cells were synchronized to G1/S, S and G2-phases by 
double thymidine block and release. Briefly, cells were grown in 2 mM thymidine for 24 
hr. After the first block, thymidine was removed and cells were released for 12 hr in fresh 
medium. Further, 2 mM thymidine was added again for 24 hr to synchronize cells at G1/S. 
The cells were released in fresh medium for 3 hr to collect them in S phase and 8 hr for 
G2 phase. 
3.4.2 Poly(A) RNA Purification 
The fractionation of poly(A) plus versus minus RNAs were performed using NucleoTrap 
mRNA kit (Clontech). After the purification, the yield of both fractions were quantified, 
and equal amount of RNA were taken for RT and qPCR analysis, and the fold of 
enrichment in either poly(A) plus or minus fractions were calculated by normalization the 
qPCR values of each fractions to the yield of the corresponding fraction. 
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3.4.3 RNA FISH 
32 smFISH probes, spanning and antisense to lncRNA S7 , were designed using Stellaris 
Probe Designer and ordered from Biosearch Technologies 
(http://www.biosearchtech.com). Probes were 20 nucleotides in length and their 3’ ends 
were modified with mdC(TEG-Amino).  Probes were dissolved individually in water to 
a final concentration of 100 μM. Equal volumes of each probe were combined for 
labeling. About 1/9 of the reaction volume of 1M sodium bicarbonate (pH = 8.5) was 
added such that the final concentration of sodium bicarbonate was 0.1 M. 0.05mg Cy®3 
Mono NHS Ester (GE Healthcare, Cat#: PA13101, dissolved in 1μl DMSO) was then 
mixed with 25 μl of the above probe solution. The labeling reaction was incubated in 
dark at 37 °C with gentle vortexing overnight. The labeling reaction was stopped with the 
addition of 1/9 reaction volume of 3M sodium acetate (pH = 5), followed by ethanol 
precipitation. Labeled probes were further purified from unconjugated free dye via P-6 
Micro Bio-Spin Column (Bio-Rad). Probes concentration and labeling efficiency were 
determined by Nanodrop. 
HCT116 cells were grown on coverslips, with or without 24 hours treatment of 0.5 μM 
Doxorubicin. At harvest, cells were rinsed once with PBS, and then fixed with 75% 
methanol + 25% glacial acetic acid for 10 min at room temperature. Then cells were 
washed once with Washing buffer (10% formamide in 2X SSC). Probe was added to 
Hybridization buffer (10% dextran sulfate, 10% formamide in 2X SSC) with a final 
concentration of 125nM. Then the hybridization was set up in a humidified chamber, in 
dark at 37 °C for 2 hours. After the hybridization, the coverslips were transferred into 
fresh plates and washed with Washing buffer by incubation in dark at 37 °C for 30 
minutes. Then DAPI nuclear stain (Washing buffer with 20 ng/ml DAPI) was performed 
with another 30 minutes incubation in dark at 37 °C. Finally, the coverslips were rinsed 
with 2X SSC, and mounted with VECTASHIELD antifade reagent (Vector Laboratories,  
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Cat#: H-1200). Images were taken using Zeiss Axiovert 200M microscope, with Cascade 
512b high sensitivity camera. 
3.4.4 Chromatin fractionation 
U2OS cells were resuspend with solution A (10mM HEPES pH7.9, 10mM KCl, 1.5mM 
MgCl2, 0.34M sucrose, 1mM DTT, 10% glycerol and 0.1% Triton X-100) and incubate 
on ice for 5min. The cytoplasmic fraction (S2) were then separated from the nuclei by 
centrifuging at 4°C at 1400g for 4min. Isolated nuclei were then washed with solution A 
without Triton X-100. The nuclei pellet was resuspend with solution B (3mM EDTA, 
0.2mM EGTA, and 1mM DTT) and incubated on ice for 30min. the nuclear soluble 
fraction (S3) were then separated by centrifuging at 4°C at 1700g for 4min. The isolated 
chromatin fraction was then washed with buffer B. The chromatin pellet (P3) was finally 
resuspend in solution A and sonicate for 1min to get the lysate. 
3.4.5 DNA fiber assay 
U2OS cells were labeled with 25mM CldU for 30min followed by 24 hours of 2mM HU 
treatment, and then released for 30 minutes in presence of 250mM IdU. DNA fibers were 
prepared using the FiberComb molecular combing system (Genomic Vision) as per the 
manufacture’s protocol. 
3.4.6 Biotinylated RNA pulldown 
S7 was amplified with primers containing T7 promoter sequence and used as template for 
the MEGAscript T7/SP6 Transcription Kit (Ambion) with the Biotin RNA labeling mix 
(Roche). In vitro transcribed RNA was purified with the G50 columns (GE Healthcare). 
2μg purified biotinylated RNA was used for each pulldown. One 15 cm plate of HCT116 
cells at 80~90% confluency were harvested by scraping. Cell pellet was resuspended in 
1ml RSB buffer (10mM Tris-HCl (pH 7.4), 100mM NaCl, 2.5mM MgCl2), then digitonin 
was added to a final concentration of 40μg/ml. After removing the cytoplasmic solution 
fraction, the nuclei pellet was resuspended in 1.5ml RIP buffer (150 mM KCl, 25 mM 
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Tris pH 7.4, 0.5 mM DTT, 0.5% NP40), and sheared by douncing (tight, 6-10 strokes). 
Nuclear membrane and debris were pelleted by centrifugation at 14,000 RPM for 10min 
at 4°C. Nuclear lysate was then precleared by incubating with 40µl of streptavidin beads 
(Dynabeads M-280 streptavidin, Invitrogen) at 4°C for 2hrs with rotation. Meanwhile, 
block the beads for pulldown with 0.5mg/ml BSA and 0.05mg/ml yeast tRNA in RIP 
buffer for 3~4 hrs. Then the precleared lysate was incubated with the 2μg biotinylated 
RNA and incubated for 2~3 hrs. Blocked beads were then added and pulldown was 
performed at 4°C overnight. Then the beads were washed with high salt buffer(0.1% SDS, 
1% Triton X-100, 2mM EDTA, 20mM Tris-HCl (pH 8.0), 500mM NaCl), low salt 
buffer(0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris-HCl (pH 8.0), 150mM 
NaCl) and TE buffer, 10 mins each. (RNase Inhibitors, protease and phosphatase 
inhibitors were included in all previous steps). Then SDS loading buffer was added to the 
washed beads, and the sample was boiled at 95°C for 5min, followed by mass 
spectrometry analysis or western blot analysis.  
3.4.7 Chromatin immunoprecipitation of DDX5 
Three 10cm plates of U2OS cells at 90% confluency which were synchronized at S phase 
by double thymidine and release, were fixed with 1% formaldehyde for 10 minutes at 
room temperature, then quenched with 125mM Glycine for 5 mins. Cell pellets were 
washed with PBS then lysed for 10 minutes on ice in buffer containing 10mM Tris pH8.0, 
10mM NaCl, 0.2% NP40, supplemented with protease/phosphatase inhibitors. Nuclei 
were pelleted by centrifuging at 4°C for 30 seconds then each suspended in 0.5mL buffer 
containing 50mM Tris pH8.0, 10mM EDTA, 1% SDS, protease/phosphatase inhibitors 
with rotation for 20 minutes at 4°C. Lysates were diluted to 1mL with dilution buffer 
(20mM TrispH8.0, 2mM EDTA, 150mM NaCl, 0.01% SDS, 1% Triton X-100, and 
protease/phosphatase inhibitors) then sonicated with a Bioruptor UCD-200 at 4°C set at 
high power for 40~45 cycles of 30 seconds on and 30 seconds off. Samples were clarified 
by centrifugation in a microcentrifuge at 4°C for 5 minutes. Supernatants were 
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pre-cleared for 2hrs at 4°C with 80µL of slurry of protein G Dynabeads (Life 
Technologies). Pre-cleared nuclear extracts were further diluted to 2mL with Dilution 
buffer then 1mL per extract was incubated with DDX5 antibody (Bethyl Lab, Cat#: 
A300-523A, 5μg) or IgG control overnight with rotation at 4°C. 10µL of diluted and 
pre-cleared nuclear extract was kept for use as 1% input for Q-PCR analysis. One the 
next day, the protein complex bound by antibody was pulled down by 40µL slurry of 
protein G Dynabeads for 2 hrs at 4°C. Following immunoprecipitation the beads were 
washed once with low salt buffer (20mM Tris pH8.0, 150mM NaCl, 2mM EDTA, 0.1% 
SDS, 1% Triton X-100, protease inhibitors), twice with high salt buffer (low salt buffer + 
500mM NaCl), once with Lithium Chloride buffer (10mM Tris pH8.0, 250mM LiCl, 
1mM EDTA, 1% deoxycholate, and 1% NP40), then twice with 10mM TrispH8.0, 1mM 
EDTA buffer. Chromatin was eluted in elution buffer (1% SDS, 0.1 M sodium 
bicarbonate) at 65 °C twice, 10 min each. Cross-link was reversed with 0.2 M NaCl 
overnight at 65 °C. The eluted material was RNase A-treated followed by Proteinase K 
treatment at 42 °C for 2 hrs. DNA was purified using QIAquick PCR purification kit 
(Qiagen). ChIP-qPCR results were represented as percentage of IP/input signal (% input). 
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3.5 Figures 
 
Figure 3.1 S7 is an S-phase lincRNA, and is induced upon DNA damage. (A) 
Transcriptome microarray analysis identified lncRNAs with cell cycle phase-specific 
expression in U2OS cells. (B) S7 is upregulated at S phase as determined by RT-qPCR. 
(C) The genomic landscape of human S7 in UCSC genome browser. (D) S7 is enriched in 
the polyadenylated fraction. Poly(A) plus verse minus RNA fractionation in U2OS cells 
followed by RT-qPCR showed the enrichment of S7 in poly(A) RNA fraction. 18srRNA 
and GAPDH were used as controls to show the purity of fractionation. (E) (Ea) qPCR for 
S7 and p21 in HCT116 wild type cells treated with DMSO, 0.5 μM Doxorubicin, 20 μM 
Etoposide, and 2mM Hydroxyurea for 24 hours. (Eb) qPCR for S7 in HCT116 p53-/- 
cells treated with DMSO and 20 μM Etoposide for 24 hours. (Ec) smFISH of S7 RNA in 
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Figure 3.1 (cont.) HCT116 wild type and HCT116 S7-knockout (S7-KO) cells treated 
with DMSO, 0.5 μM Doxorubicin for 24 hours. S7-KO cell was used as a negative 
control for S7 smFISH, and will be described in Figure 3.2C. (This experiment was done 
in collaboration with Dr. Arturo Orjalo from Biosearch Technologies.) (F) qPCR for 
mouse S7 (mS7) in transformed MEF cells treated with DMSO, 2 μM or 20 μM 
Etoposide for 24 hours.  
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 Figure 3.2 Depletion of S7 results in defects in cell cycle progression. (A) (Aa) qPCR 
for S7, (Ab) PI-flow cytometric analysis of cell cycle, (Ac) BrdU pulse labeling of S 
phase cells, in U2OS cells transfected with negative control (NC) siRNA, siRNA-7b 
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Figure 3.2 (cont.) and siRNA-7c targeting S7. (B) (Ba) PI-flow cytometric analysis of 
cell cycle in HCT116 wild type cells transfected with NC siRNA, siRNA-7a and 
siRNA-7b. (Bb) PI-flow cytometric analysis of cell cycle in HCT116 p53-/- cells 
transfected with NC siRNA, siRNA-7a and siRNA-7b. (C) (Ca) qPCR for S7 in wild type 
HCT116 cell (neg, negative control of S7-CRISPR KO), and clone 10 and clone 11 of 
S7-CRISPR KO HCT116 cells (cl10, cl11, two independent clones of S7-CRISPR KO 
lines), treated with DMSO, 20 μM Etoposide, and 2mM Hydroxyurea for 24 hours. 
(These S7-CRISPR KO lines were made in collaboration with Qinyu Hao.) (Cb) PI-flow 
cytometric analysis of cell cycle in wild type HCT116 cell, cl10 and cl11 of S7-CRISPR 
KO HCT116 cells. (D) Western blot for p53 and p21 in HCT116 wild type cells treated 
with NC, si7a and si7b siRNAs. (E) Alkaline comet assay for U2OS cells transfected with 
NC and si7b siRNAs. (F) Western blot for Orc2, MCM3 and SRSF1 on cytoplasmic (S2), 
nuclear soluble (S3) and nuclear insoluble (P3) fractions from U2OS cells transfected 
with NC, si7b and si7c siRNAs. SRSF1 was used as a loading control. (This experiment 
was done in collaboration with Dr. Arindam Chakraborty.  
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 Figure 3.3 Depletion of S7 results in defects in DNA damage response.(A) PI-flow 
cytometric analysis of cell cycle in U2OS cells transfected with NC or si7b siRNAs for 1 
round of knockdown, followed by 24 hours of 2mM HU treatment, and released for 0, 12 
and 24 hours. (B) DNA fiber experiment of U2OS cells treated with NC or si7b  
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Figure 3.3 (cont.) siRNAs. U2OS cells were transfected with NC or si7b siRNAs for 1 
round of knockdown, then pulse-labelled with CIdU (green) for 30 minutes, followed by 
24 hours of 2mM HU treatment, and then released for 30 minutes in presence of IdU 
(red). DNA fiber spreads were prepared (Ba), and the percentage of new origins (Bb) and 
the tract length of CIdU and IdU fibers (Bc) were determined. (This DNA fiber 
experiment was done in collaboration with Yo-Chuen Lin.) (C) Western blot for 
phospho-Chk1 at Ser345, Chk1, phospho-BRCA1 at Ser1524, RPA32 and γH2AX in 
U2OS cells transfected with NC, si7b, or si7c siRNAs, followed by 24 hours of 2mM 
Hydroxyurea treatment. Tubulin and β” were used as loading controls. (D) MTT assay for 
HCT116 cells transfected with NC or si7b siRNAs, followed by DMSO (Ctr) or 
Doxorubicin (Dox) treatment. (E) Clonogenic assay for HCT116 transfected with NC or 
si7b siRNAs, followed by DMSO (Ctr) or Doxorubicin (Dox) treatment. (These 
experiments in (D) and (E) were done in collaboration with Dr. Xiao Ling Li from NIH.)  
 
 
 
 
 
 
 
90 
 
 Figure 3.4 S7 specifically regulates a group of cis genes involved in cell proliferation 
and DDR. (A) Illustration of samples collected for microarray analysis. HCT116 cells 
transfected with NC or si7b siRNAs for 2 rounds of knockdown followed by growth for 1 
day, 1 round of knockdown followed by growth for 1 day, and 1 round of knockdown 
followed by 0.5 μM Doxorubicin treatment for 1 day, were collected for RNA extraction 
and microarray analysis, meanwhile the cells’ cell cycle status were analyzed by PI-flow 
cytometry.(B) Top significant molecular and cellular functions for genes whose transcript 
levels were reduced in si7b-treated HCT116 cells comparedto NC, after 1 round of 
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Figure 3.4 (cont.) knockdown followed by growth for 1 day (left panel), and 2 rounds of 
knockdown followed by growth for 1 day (right panel).  (These microarray analyses 
were done in collaboration with Dr. Ashish Lal from NIH.) (C) qPCR for cis genes of S7 
which are involved in cell proliferation and DDR, in HCT116 wild type cells transfected 
with NC, si7a, si7b siRNAs. The approximate genomic positions of the genes are 
illustrated in the top panel. (D) qPCR for genes surrounding and in between S7 and WTIP, 
in HCT116 wild type cells transfected with NC, si7a, si7b siRNAs. The genomic 
positions of the genes are shown in the top panel. 
 
 
 
 
 
 
 
 
 
 
92 
 
 Figure 3.5 S7 positively regulates WTIP, acting as a native regulator of Hippo 
signaling. (A) (Aa) qPCR for S7, WTIP, YAP1 and YAP1 targets CCND1 and CTGF 
(left panel), and E2Fs targets (right panel) in HCT116 wild type cells transfected with NC, 
si7a, si7b siRNAs. (Ab) qPCR for S7, WTIP, YAP1 and CCND1 in HCT116 p53-/- cells  
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Figure 3.5 (cont.) transfected with NC, si7a, si7b siRNAs. (B) Western blot for WTIP, 
CCND1, YAP1, and phospho-YAP1 in HCT116 wild type cells transfected with NC, si7a, 
si7b siRNAs. β” was used as loading control. (C) qPCR for additional YAP1 targets in 
HCT116 wild type cells transfected with NC, si7a, si7b siRNAs. (D) CTGF promoter 
luciferase assay. Wild type CTGF promoter (WT) or TEAD-binding sites mutated CTGF 
promoter (mut) was cloned into a basic luciferase reporter. These WT or mut reporters 
were transfected into U2OS cells pre-treated with NC, si7b, si7c siRNAs. The relative 
luciferase activities were shown. (E) Western blot for WTIP in HCT116 wild type cells 
transfected with NC siRNA or siRNA targeting WTIP (dsiWTIP). (F) qPCR for WTIP, 
YAP1 and YAP1 targets CCND1 and p15PAF in HCT116 wild type cells transfected 
with NC siRNA or dsiWTIP. (G) PI-flow cytometric analysis of cell cycle in HCT116 
wild type cells transfected with NC siRNA or dsiWTIP. (H) qPCR for WTIP, YAP1 and 
YAP1 targets CCND1 and CTGF in HCT116 wild type cells transfected with NC siRNA 
or smartpool siRNA targeting WTIP (psiWTIP). (I) PI-flow cytometric analysis of cell 
cycle in HCT116 wild type cells transfected with NC siRNA or psiWTIP. 
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 Figure 3.6 S7 promotes WTIP transcription through interacting with DDX5. (A) 
qPCR for WTIP and p21 in the nascent RNA captured from HCT116 wild type cells 
transfected with NC or si7b siRNAs.(B) Western blot anlysis of DDX5 and αTubulin in 
biotinylated RNA pull-down of S7. αTubulin serves as a negative control. (The 
biotinylated RNA pull-down experiment was done in collaboration with Dr. Ritu 
Chaudhary from NIH.) (C) DDX5-RIP in HCT116 wild type cells followed by 
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Figure 3.6 (cont.) (Ca) western blot for DDX5 and (Cb) qPCR for S7 and 18sRNA. 
18sRNA serves as a negative control for the binding of DDX5 to unspecific RNAs. (D) 
DDX5 ChIP-qPCR at CDC6 (positive control locus), CD4 (negative control locus), 
WTIP promoter (WTIP-upstream pro), WTIP 1st intron and WTIP 12kb downstream 
regions (out-of-ORF negative control), in U2OS cells synchronized in S phase. (E) qPCR 
for DDX5 and WTIP in HCT116 wild type cells transfected with NC or siDDX5 siRNAs. 
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Figure 3.7 S7 contributes to tumorigenicity in vitro and in vivo. (A) 
Anchorage-independent growth in soft agar of wild type, cl10 and cl11 of S7-CRISPR 
KO HCT116 cells.(B) Tumor formation of wild type control, and cl10 of S7-CRISPR KO 
HCT116 cells in mouse xenograft experiment. (This experiment was done in 
collaboration with Dr.Anindya Bagchi lab.) (C) Gene amplification analysis of KCTD15 
and LSM14 which are protein-coding genes flanking S7 in different cancer subtypes. (D) 
Correlation analysis of S7’s expression level with patients’ survival in colon 
adenocarcinoma. (These analyses in (C) and (D) were done in collaboration with Dr. 
Sasan Hashemi and Dr. Sarath Janga from Indiana & Purdue University.) 
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CHAPTER 4. CONCLUSIONS AND PERSPECTIVES 
Eukaryotic genomes are pervasively transcribed to produce diverse lncRNAs. Although it 
still remains undetermined how many of these lncRNAs are functional, it is suspected 
that they are involved in several crucial cellular processes. With that in mind, I began my 
research by asking: “how are lncRNAs regulated?” and “which are the functional 
lncRNAs in certain cellular process, and how do they exert their functions?”.  
To explore the mechanisms of how lncRNAs are regulated, I studied the maturation event 
of lncRNA MALAT1. MALAT1 is a highly abundant lncRNA, which localizes to nuclear 
speckles and is implicated in pre-mRNA splicing and transcriptional activation of genes 
involved in cell-growth and proliferation (Li et al, 2009; Tripathi et al, 2010; Tripathi et 
al, 2013; Yang et al, 2011b; Zong et al, 2011). The strikingly high cellular accumulation 
of MALAT1 [MALAT1 exists in ~2500-3000 copies per cell (Tripathi et al, 2010), with a 
half-life up to 16.5 hours (Gutschner et al, 2013)] has been attributed to an unusual 
processing and maturation event at its ultra-conserved 3’ end, which involves the 
cleavage of mascRNA, a tRNA-like structure, out of the primary transcript, followed by 
the formation of a bipartite triple helical structure at its 3’ end, which confers resistance 
against exonucleases-mediated RNA degradation (Brown et al, 2014; Brown et al, 2012; 
Wilusz et al, 2008; Wilusz et al, 2012) . In Chapter 2, I identified TALAM1, a NAT from 
the MALAT1 locus, as an important positive regulator of MALAT1 through promoting its 
3’ end processing event, which is crucial for its stability. TALAM1 was found to be 
essential for the cellular accumulation of MALAT1 and could potentiate the stabilization 
effect of MALAT1 3’ end sequence towards labile RNA. Further, TALAM1 itself is 
positively regulated by MALAT1, thereby forming a feed-forward regulatory loop to 
maintain the high cellular levels of MALAT1.  
It remains to be elucidated how TALAM1 modulates the 3’ end cleavage of MALAT1. 
TALAM1 RNA concentrates predominantly at the MALAT1 gene locus and could form 
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RNA duplex structures with MALAT1 RNA. At the same time, exogenous expression 
studies indicate that TALAM1 could also exert its function in trans. It is possible that 
TALAM1, by interacting with MALAT1, modulates the secondary and tertiary structure 
of MALAT1 RNA, and this could influence the recognition of mascRNA by RNase P. It 
is also possible that TALAM1 may facilitate the recruitment of specific components of 
the RNase P complex or its cofactors to MALAT1 RNA, or act as a decoy to sponge 
inhibitory protein factors away from MALAT1 RNA. Future studies could probe into the 
mechanistic insights of TALAM1, and potentially other NATs, in RNase P-mediated 
cleavage of non-canonical substrates, including MALAT1 and additional cellular RNAs 
with ENE-like structures.  
In addition, given the fact that the aberrant upregulation of MALAT1 is observed to be 
widely associated with hyper-proliferation and metastasis in cancer, and the oncogenic 
activity of MALAT1 has been documented in several types of cancers (Gutschner et al, 
2013), it would be interesting to determine whether specific oncogenic pathways regulate 
TALAM1 levels in order to increase MALAT1 levels. In this context, it would be fruitful 
to profile human cancers with upregulated MALAT1 levels, and determine whether the 
elevated MALAT1 levels are attributed to its enhanced stability, altered efficiency in 3’ 
end processing and dysregulated expression of TALAM1. These analyses will help us to 
understand the aberrant upregulation of MALAT1 and may provide clinical clues to 
modulate its level in cancers.  
To study the roles and mechanisms of action of novel lncRNAs in vital cellular processes, 
I chose to study the functional lncRNAs in cell cycle progression. Proper regulation of 
cell division cycle is crucial to the growth and development of all organisms. 
Understanding this regulation is central to the study of many diseases, most notably 
cancer. In Chapter 3, through a genome-wide unbiased lncRNA transcriptome analysis in 
cell cycle-synchronized cells, we identified ~400 lncRNAs that exhibit cell cycle-specific 
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expression patterns. Functional characterization of one S phase-upregulated lncRNA, S7, 
revealed its important roles in regulating cell cycle progression and DNA damage 
response. S7 regulates a group of genes involved in cell proliferation and DDR in cis, 
among which is WTIP, a member of AJUBA family proteins that represses Hippo 
signaling pathway. The Hippo pathway controls organ size and tissue homeostasis in 
diverse species through regulating cell proliferation, apoptosis and stemness, whereas the 
deregulation of this pathway underlie a broad range of human carcinomas(Yu et al, 2015). 
I therefore have identified S7 as an important lncRNA inhibitor of Hippo pathway and 
thereby playing critical roles in regulating cell cycle progression and tumorigenesis. It 
would be imperative to profile the cancer types where S7 locus is amplified to determine 
whether these cancer types are addicted to the repression of Hippo pathway, and whether 
manipulation of S7’s level could provide clinical benefits to these cancers.  
With respect to the molecular mechanism of action, our results imply that the regulation 
of WTIP transcription by S7 may occur through S7’s recruitment of DDX5 to WTIP 
promoter. DDX5 is a member of the DEAD box family with RNA helicase activity. In 
addition to its crucial roles in RNA metabolism, it is becoming increasingly clear that 
DDX5 acts as transcription cofactor(Fuller-Pace, 2013). Future studies will address 
whether S7 affects the binding of DDX5 to WTIP promoter, and whether S7 is directly 
involved in the recruitment of DDX5 to WTIP promoter. For the potential direct role of 
S7 in recruiting DDX5 to WTIP promoter, it is possible that S7 RNA is present in a 
complex with DDX5 at WTIP promoter, and the presence of S7 lncRNA may either 
confer specificity in targeting DDX5 to WTIP promoter, and/or stimulate the 
transcriptional co-activator activity of DDX5. Two lncRNAs have recently been reported 
to modulate the activity and chromatin recruitment of DEAD box family proteins, 
including DDX5(Huang et al, 2015; Marchese et al, 2016). We therefore speculate that 
the mode of action of S7 may represent a more widely spread mechanism in which  
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lncRNAs interacts with the DEAD box family DNA/RNA helicases to modulate their 
location and activity.   
Furthermore, as exemplified by S7, it would be fruitful to characterize the other cell 
cycle-regulated lncRNAs identified in our study in the future, which may reveal 
additional lncRNAs that are important for cell cycle regulation and cancer development.   
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